( 12 ) 55i§ﬁE9ij1 913 } °=1 %7H€=l %X11‘?= } - _‘ - %. . . X A A “x ( 19 ) 1111111 ] ﬁ } fﬂ$§1ﬂ7 ] ? iiiiiiiii lllllllllllllllllllllllllll111111L|1| [ U|lﬂ ] |ﬂﬂ|ﬂﬂ||llllllllllllllllllllllllllll. o 3. 2013 B g4%j01 ] § 11E052013 ) Wm0 I P CT W0 2013 / 077617 A1. ( 51 ) i“1l%31v‘i‘ - 1Er= ( 81 ) M51 ( BEa EN71 BB 62 , 7 } %6& BB aaa A61K38 / 13 ( 2006.01 ) A61K39 / 395 ( 2006.01 ) BB BBB BBB % BB ) : AB , AG , AL , AM , 0 , A6IK3 ] / 44 ( 2006.01 ) A6 ] P ] 7 / 00 ( 2006.01 ) AT , AU , AZ , BA , BB , BG , BH , BN , BR , BW , BY , BZ , ( 21 ) %11l %%ﬂi : PCT / KR2012 / 009842 gg gg , E%LE ( ( : } Ni3 ( s : O151C ( § ] 33C ( I } Jf ) Cé ; [ 2% IGIixT DG1\$ %% ( 22 ) %Zﬂ%ﬂa : 2012 a 11 a 20 02 ( 20.11.2012 ) 1111111111115 , 1L , 1N , 1s , 1p , 1<13 , 1<G , 1<M : KN : KP : KZ : ( 2s ) %%l?i°=l : iiiitOi RR‘fW. L1I } W‘ : §WES1WWTW‘2‘fW‘£W“é?W¥£0E 1111 ( 26 ) %7 ' | ] ¢1_ : I_O3|. @ ; LO1 PA , PE , PG , PH , PL , PT , QA , RO , RS , RU , RW , SC , SD , WWW WW R ; 2W ; 2WTN=. 10—2011—012244720111 : j11% 22% ( 22.11.2011 ) KR ( 84 ) z ] : §a ( ua : q EAm ﬁﬁ a ) 7 } : a ) m ; BBB E - J— . u. H L. L , L + 1‘ 0. ( 71 ) éﬂﬂ : %%EH ' 3 } 3 : 1 ﬁﬁﬁﬁﬁ ( D0NGGUK UNI - 9% a BB ﬂ BBB B 31°1 ) : ARIPO ( BW , GH , GM , VERSITY INDUSTRY - ACADEMIC CO0PERATION KE , LR , Ls , MW , MZ , NA , RW , SD , SL , sz , TZ , UG , FOUNDATION ) [ KRfKR ] ; 100 - 715 Ai%>\1 %? %% 3 ZM , ZW ) , %EJM ] o } ( AM , AZ , BY , KG , KZ , RU , TJ , 7 ) 26 , Se0u1 ( KR ) . TM ) , BB ( AL , AT , BE , BG , CH , CY , CZ , DE , DK , EE , . ( 72 ) %% Z } ; ° ] °H‘§ ( LEE , Ai - Y0ung ) ; 110_044 * 1% * 1 gO ; f. ; ES , FI , FR , GB , GR , HR , HU , IE , IS , IT , LT , LU , LV , MC , . T %%% 254 R1421 ﬂ%O1‘%“EI‘O1‘ OTﬂE 801 § , Se0u1 ( KR ) . ( 74 ) EHi ' Jﬂ : 4 - 03 - 8 - ( KIM , So0n W00ng ) ; 152 - 766 H %A ] €3 , 711. $$$ %i% 197—22 Biz ) °iI°1i2Ei1ELiE15H 5 i ) 601 3 : , Se0ul ( KR ) . — j??<i1é17 : / \1lﬂnﬂ * 191 ﬂﬂﬂ ( 3 : C%k 111 21 Z : ( 3 ) ) . MK , MT , NL , NO , PL , PT , R0 , Rs , SE , SI , sK , sM , TR ) , 0API ( BF , BJ , CF , CG , CI , CM , GA , GN , GQ , GW , ML , MR , NB , SN , TD , TG ) . . 0 2013 / 077617 A1 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| |||||||||||||||||||||||. ( 54 ) Title : COMPOSITION FOR PREVENTING , TREATING OR ALLEVIAT1NG ATOPIC DERMATITIS COMPRISING IMMUNOSUPPRESSANT AND TRANSGLUTAMINASE 2 INHIBITOR. ( 54 ) a1=aa BB : BBBBB a ERHA§$E1DIL1I1I 2 cARIRI§ BBBB o + EEI BBB 2I 01IBhiIE EEE 7H + _% E gg. . . ' 11 + 2a ( s7._251 7 ' 1 - 1113 mm - 1=30.1s51 - .5J. ( 57 ) Abstract : The present inVenti0n re1ates t0 a c0mp0siti0n f0r preVenting , treating 0r a11eViating at0pic dermatitis c0mprising an immun0suppressant and a transg1utaminase 2 inhibit0r as actiVe ingredients. C0nj0int administrati0n 0f an immun0suppressant and a transg1utaminase 2 inhibit0r acc0rding t0 the present inVenti0n makes it p0ssib1e t0 achieVe far better therapeutic effects than With administrati0n 0f either an immun0suppressant 0r a trans g1utaminase 2 inhibit0r a10ne , since there is a reducti0n in the d0se 0f an immun0suppressant Which is difficult t0 administer f0r a 10ng time because 0f side effects and With Which , When disc0ntinued , 1e - si0ns are iiab1e t0 bec0me eXacerbated t0 the 0rigina1 state , and since an immun0suppressant is miXed With a transg1utaminase 2 in - hibit0r Which in s0me patients has a 1ack1ustre effect in treating at0pic dermatitis. ( 57 ) 3 - 9V°1 : . ma 2 mm. W0 2013 / 077617 A1 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||. . . 1 11 a 11111 aaaaaawa 11111 211B 11191 21z11s1 BB 11111111 111 %% AA 333% aaa a 1111. 2 11 WWEaAB - 1E1111112 1 aaaa 1111111113 BB 111 131 , %% A1 11112 : aaa aaaa 111 aaa21121a %%£ BB 1o11 11111 L %§r 1111. B E 1 111 11$ 44 111 111 N E R 1 W 1111 m g MM. [ 1 ] . [ 2 ] . [ 3 ] . [ 4 ] . [ 5 ] . WO 2013 / 077617 PCT / KR2012 / 009842. E8‘ * 1 * 1. BB BBBBBBB BBBBBBBBBB 2 BBBB BBB B BBB BBBB BBBBBB BBBBBB. BBBB. B BBB BB B211x11 B BBBBBBB BB 2 BBBB BBBBBB BBBB BBB BBBB BB BB BB BBB BBBB BB BBB BBBB. O Eﬂ TJ‘1l1j—?§ ( : 11t0pic dematitis ) % %%31_9.§ %% %%ﬂ 7oL§Z iOObQ% BBB BB BBB ZiEE , BB BBB BBB BBBB BBBB BBB % E01U1 ( Lancet. 1998 ; 351 : 1715 - 17 1 ) . O1E§1 T %%% 7715‘1—E ‘ : { 141 §§13§ , %§ ‘330111 7%01°11711 * 1 O ] O11f1 . O1 4 H _. W10 101 H. / B$BBBBBﬂBBBBBBBBBBBBBBBBBBB%mBB$B % , 9_§ ‘$1511 11 ﬂﬂ % * §%O1 73 ] ?“ Q ﬂﬂ 1 14121 3% EEE ( Immun01. A11ergy. C11. 1mmmnmmnma@B&BBBBBBB2BB%M ; : BBBq BBBB%WHmmame%mm4m1BBBoWﬁHBBB?BBB BBBBBBB%MHHE%%%BiMﬂBBBB%Bﬂ&N1 BBBBBBBBBBBBBJMNWWBBBBBWVHhBBB£B BBBBBBB%ME¥$$BﬂB%%B : iBﬂ£@%BBBBBBB BBBBBBBBBBBBBBBBBWLﬂBBBB&BBBBBBBWBBBBBﬂ%BﬁBEWH$%#%BBBBBBBBBBBB%ﬂE , BBBBHEE : ﬂBBBWUFBBB%B€£5B%%B%B%PhH3 721 01131 ( LanCet. 1998 ; 351 : 1715—1721 , J. Pediatr. Hea1th Care. 2002 ; 16 ; 143—145 ) . BBB BBBB BBB BBB BBBB BBBB BB BBB BBBB %9%BBBBBBBBBBBBBBBB?BBBBBﬂBBBB BBBBBBBBBBBBH0HMVN¥%BBBBB%Bﬂ%B BBBB. BBBBBBBB2H¥M§BBBBBBBBB£ﬁEwE ; BﬂBB%ﬁ , BBBBBBBBBBBBB%%WW1BB£ BBBBBBBBBBB BBBBBBBEBBBBBBB£EiBBBBBB2BBBBBBBB 1£%%BBMBBﬂ&N1 : BBﬁHW1 BBB BBBBBBBBB. EmE¥€K BBBﬂ ooB~114 £§ &§—51“EH1 E%% 1Z‘—1Lf 513i / ‘1 , §§ZH7J ] - 7\ ] O } Eﬂ ﬂﬂ S %Z } %Q PﬁL§ BBB BBBBBB BBB BBB. WO 2013 / 077617 PCT / KR2012 / 009842. [ 6 ] . [ 7 ] . [ 8 ] . [ 9 ] . [ 10 ] . [ 11 ] . 11BHBmBBPO1VWB o1BBBBBBBBB BB BBBBBBBBBBBB BB BBBB 54Eﬂ : 1?%i1EBE<mBBB1. 2 111 BBB 1111111 A —1 111 jjj A0. 111. 111 11. W1X112O08—O035997§ ) .1131L1 , % * Er3i / \E BBBB%mBBBBBBBBmm1 BBB1BwHBBBBBBBBBBBBBBB 1. A B3 Bo BB _1_ , —E‘. r1o. H13. 111. 1$A_111o1 r1r BBBA rO1 E B A111 1 : 1 11111 o111j01 A. 1 : 1. .>~ FA. HU£ - 101J101 AﬂﬂmBA. 1111§91_> : . ¥F r r A 1111. 11A U10 ii cﬂ 111 111111 _O1 £1111“. AmE‘ : . 11111 oE ' . JA1E AJAOB 1FA - A r01. m3 : . oEL. EB B B B A B A. 1111 111. BB 1111o 11 A 1101 BB 1110. O. i 11 E 1r 110 1111 1111 11111. A AAA rE13A12imi 1BBBBB. BB 1B 111 0A ii 121911‘. 11111 F - BBB. FE A E. A A ‘Ar§ ' £_0 , u2i. JEoAﬁEAr. oA O10‘ 111A - BBB c113 “. ﬂ . 1R 1 A A 11111 1111 ii B. 1 BB 111 111 oE. ﬁﬁ. 11 E L J1U. A. r1o. a 1R 119 A A. A 1111 F 101 11 1111111 , 111 1113 J B A 111 E 111. 111. r_> : . 1B F11I 1 o 111 111 11 B A 111 A 1111 1 A 1111 R A 1111 Bo J91 B A W A 1111 >13 A 1111 11 A 1111 1111. O10 c131 E A 1N 1 oZ : 11 H1113 1110 A oH , A 111 E1 3 u L. A. 11 A A - 1> Bl. 0 * ?. \1. BZA B. 1 1111 —1111 111 1111 A. BBo E L é 11113 N _15Z E l A 11111 : 10 1101 oA 11E W 1O 11. 111 1A. 1P1 1111. A 11111 BBB 3 B 111 c133 BB 1110 A B rO1 L. 1111BJ. 1P1. 1 BB 111 1111 111 r1o. A E A. EEE E A A A 1111 A 1> 1111 —1111 A E L A N. v 15Z A A 11111 : 10 111 oEL r1111 : 1o 1111. 1111 111 010 A 0A F 11111 11 n11 : 1110 A B rO1 L. B g 91 B. 1101 o1o BB ﬂ. oA JR \1. $E1U1L1X1129B1X11X1H 33%—E1 * O1 * E , E , %%1OJ } \1 - O§_H= ] HﬂO1 O ] - §1_E171 : H_E_ ‘31 X11 M11 “1 : EBL : %$ﬂU1%X112. ‘J17<1E E E711 d£LJ1i§ BBB. B B 12 A 1111. O oE. 18 A A B 1111 F W. °r3ﬂ—1‘ * l. 19 ; A _1m O11 } BL 1111. A1111 BB. 11. 11% BB 1111 BA B1 A 11 w 0 AA 0 19 ; 1111. 12 A 1 111. 1111 B1B E. $ 1 1111. 11 111111. A ' A. 111 BB EE B E d Bl BB 1113 : oE. WO 2013 / 077617 PCT / KR2012 / 009842. [ 12 ] . [ 13 ] . [ 14 ] . [ 15 ] . [ 16 ] . [ 17 ] . [ 18 ] . [ 19 ] . [ 20 ] . [ 21 ] . [ 22 ] . [ 23 ] . [ 24 ] . [ 25 ] . E 1% BBB / \1B11500 mg / kg / day ) 3l1 BBBB B£ ( FK—506 ) ( 1.0mg / 1<g / day ) % 6. L O1 @1 + % é } U1 31 : 1 E ZF— ( c1inic211 skin sc0re ) % %% 31O1 111E631. BB BB BBB BBB B O1ED‘1 BBB NC / Nga BBBBBB BB 111 BB BBB BBB BB : 1 BBB BBB BBB EB 1 : 1. E 3% A1O1%E£E% ( CsA ) ( 10 , 45 , 100 mg / kg / day ) B. % * Erﬂ / \1‘¥_ ] ( 10O , 500 E 8. mg / kg / day ) B - BB BB BB BBB B , BB BB BB BB 1B BBB. 111 A r 1 1111 1111 111 A @ 1111o é. mg / kg / day %%9_§ .1123 * 81ﬂ , BBBBéEﬂC AM BBBBB BB B1<>1 BBB EEE BBB BBB B BB BB BBB BBB BBB BBB BBB BBB BBB. E 5 BB E 8% BB B B¢ ( FK—506 ) 1.0mg / kg / day91 BBBBB 500mg / kg / day% BB BB 1111 % B B B , 1L—5 ( E5 ) , 1L—13 ( E6 ) , TARC ( . B 7 ) B O191E1 / 1‘l ( eotaXin ) ( E 8 ) §ﬂ %§1 : % H1ﬂ§51 7gﬂ§ 11E1Hi1 EO1E1. E 9% * 1O1%EAE% ( CsA ) ( 2 , 5 , 10mg / kg / dayM BBBBB ( 500mg / kg / day ) % BB BB 111 % BB B B , 1L—5 , 1L—13 , o19_EBB ( eotax1n ) , TARC A TsLPB BBB BBB H1 BBB BBB BBB E0114. E 10% BBBB B¢ ( FK—506 ) ( 1.0mg / kg / day ) 91 BBBBBMsOomg / kg / day ) BBB EEE 111% BB * 1 , CLA + BB CD3 + TB1_B : B X1 B1 BBB BBB EB 11. E 11% BBBBB * 1O1%EﬁE% ( CsA ) ( 2 , 5 , 10mg / kg / day ) 91 BBBBB ( 500mg / kg / day ) % BB BB 111 BBB BB 711 B , CD4 + CD25 + BB T x11_B : B‘—B ZBi BBB BBB E01 111. E 12% Bl. E 13% BBBB B¢ ( FK—506 ) ( 1.0mg / kg / day ) 91 BBBBB ( 500mg / kg / day ) % BB B% BBB BB 111 111W1E BB BBBB % : 1 , %”11B ‘3121 BBB BBB E01 14. E 14% BB §iﬁE% ( CsA ) ( 10mg / kg / day ) K1 BBB BBBBB ( 500mg / kg / day ) % BB BB 111% BB } \1 , BB 111 BB1 BBB B BBB A BBB BBB BBB BBB BBB EB 111. BBB BBB E01111. E 16% * 1O1%EﬁE% ( CsA ) 31 BBBBB 111 % ( InV01ucrin ) BB BB : B ( ﬁ1aggrin ) BBB B ‘ B BBB E 17% BBB BBB BBB 711 BBBB % BBB B A1O §§AE%11 BBBA1B1% %B1 * B B. * 11%% BBB BB 1111 ‘1.1% BBBBB , . 1‘_1. 11111. ‘13 E B 18 - 8 - BBBBBBBB BBBBBB BBBB 33% BB 6. WO 2013 / 077617 PCT / KR2012 / 009842. [ 26 ] . [ 27 ] . [ 28 ] . [ 29 ] . [ 30 ] . [ 31 ] . [ 32 ] . [ 33 ] [ 34 ] [ 35 ] . [ 36 ] . [ 37 ] . EEEEnmEE E1EEEoEwEE WEE11EE5EEEEom1 EEEﬂEEEE111EE5EEﬁEE + WWh E EEEEE EEEEEE EEEEEE EEEE. 5E ( D RUG1 ) <>11 } \1E EE SCORAD EE ( o1E1 EEEE EEE EE ) 1 EE 5E ( D RUG0 ) O11 / ‘19E EE SCORAD EE ( <>1E1 EEE ) , EE EEE EE E11 EEE EEE E EE M1 EE E1ﬂ7171 : E1EE ( E ) EE1E EEE. E. E20E 11EE / EEEO11 EEE1E1E EEE EEEE 1 EE EE %%% EErO1 11 73 O T4 33 EELTﬁ ( 0bjectiVe functi0na1Va1ue ; OFV ) —% 711ﬂ ' § EEEEEEEEE. E 21E EEEEEEEE EEEEEE EEEEE E E E E EEEE EEEEEEEEEEEEEEEEEE - . E 22 EE EEEEEE EEE * 1E_ ( Z1£E_ ) E EEEE E E EEEEE. E ' ' - EEEEEE. L E. EEEEE EEEEEE EEE EEE 7E. IL 4 ( E 25 ) IL— 5 ( E 26 ) E EEE EE E EE EEE EEE EEE EEEEEE EEEEEEE. E EEE E EE EEEE EEEEEEE EE 2 EE. EEE , o1 E E E EEE 0113117<1E EE EEE EE. %% ﬁﬁﬁﬁ ZH%U. 1§17\1_§_ ggg %% EE . E i W r1r oi. E E. o1 E , E E E * 1E11E / EEE1E1. E E EEE E EEEEEE E211 2 E E 211 E EE EE EE , 1911 : w EE A1o1E71O14 H1H71§17131£§ Z } £ : ‘51711 a. E EE EEEEE EJ / g : 1E 0 EE EE1x11EE. EEE. EE ETmO1EEEEE1EE HE EEEEEEEE. E 1. E. , 031 1111. EE 118 E N. EEHﬂHﬂ ﬂ rﬁiﬁﬁ EEEEEE EEEE Efmhutm. L§p“. ﬁﬁ 91 X11X11 EEE EEErSiElH %E1 iO1‘ : ( G1uc0c0rtic0id ) , * 101—§L §ﬁE% ( Cyc10sp0rine ) , 131ELEﬂl11 Macr01imus , FK506 ) , J1 13111ﬂ%ﬂu i ( PimeCr01imus ) , ISA ( TX ) 247EQ * ( E§j15JE 71‘ ) \1‘1Ta ( C8. iCi116u1‘i11 ) m X11X11 , 131‘j113101£1 ( Rapamycin ) , E10E1 IV PDE m X11X11 ( Type IV PDE inhibit0rs ) , 13101ﬂ§11l§311 O1E E E1% ( Myc0phen01ate M0feti1 ) , ‘31 * 113117313 ; E% O11 / ‘16E 61 * A T9l311 , 01O11 EEEEEEE—EEEEEEEEEEEEEEEEE - . EE 1 EE EEEEEE E EEEE EE EEE 2 E EEE EEEEEE &61 - Of1 , ; o ] % : LLﬁ : O1o13j H1. Bu1r ; <151_71 ] 3 : _ ) 517 ] Eﬂ§<§>_ [ 4z11x11§ / 11 A1O1§LEﬁEQ9rE£EE19r£ﬂ3V1U11E1€E EEEEEE EE EEE EEE. WO 2013 / 077617 PCT / KR2012 / 009842. [ 38 ] . [ 39 ] . [ 40 ] . [ 41 ] . [ 42 ] . [ 43 ] . m 15 r111. 55 O1%1% 555555 91131. ”E511 : 3 : % * Er131131 L17<11 2 ( t1ansg1utam1nase 2 , O1 51 TG2 ) O1 Z11Z11” : TG2Q. 55 111 EE TG24 H151 5x11 211 5 55 : 5151U1 TG2 * — X15 55 51 : !17191 11101X1 7171512515 7Lu1. a 01 51 ( 8— — - 1 { - —g1utamy1 1ys1ne ) 5 Q1 511 : ‘ 721% 555115111 : § ; ( Meth0ds in. 1110.1 1985 ; 113 : 358 375 ) 5 5H 555 55555 555 555 555 555. O 1111 O171Z131 3 , 151 ( FASEBJ. 1999 ; 13 : 1787 - 1795 ) . 11311 - 1. 51%11515TG25 - 51551E57351 O : 1% / K17<1§_X1_71tﬁ<3=1 ; §1§—ﬂ. o§ 111 %% : 1 E1 71Z1 321514 111E11111OO11 7101511131 ( Neur0che1n. Int. 2002 , 40 : . 55 i. 5555 Eo 555. 55555 WUFEmE : 10o21110% —111113503 : . 111 o2 : 55. 00 M H 1 : 80 \ : _ / . 11E . o$L ' 1111‘. 51X1 TG2£55E1 51191 5 —GT G2 Q1X11OE1 5? 9151. 55E 011 * 1 —51—TG2 Q1X11 - 1E§L 131%3115 5511 E1315 %5 Q1X1 X11‘?21 55 3151. E ‘51 O11 / ‘1 55 55 X1h1~1 , — : — 551‘ 1X5O§X11&5 : >151. ELD1E TG25 Q1 / 515X11X11t TG25 Q1 / 5% 5X11511 : 1“515j1 , %i51 51% 555 , 1Z : E1131 ( cystam1ne ) , TEE11 / ‘1 ( putresc1ne ) , EiE1§?1E1511%. ( n10n0dansy1CadaVer1ne ) , 55 H1133101U1 L : O1E 71 011 : 11 ( w— —d1benzy1an11n0a1ky1am1ne ) , . 555555 5113i O1 * 5~. : * 1—7£ ( 3 —ha10— 4 , 5 - - d111ydr01s0XaZ01e ) , . 2 - [ ( 2 - % / ‘ j E5 ) 151O ] O151 1117‘ a % 191 - EX11 ( 2 - [ ( 2 - 0X0p10py1 ) th10 ] 11n1daz011u1n. de11V21t1Ves ) C ~3% OL1_‘E1Q1 } ‘ 9 , 151.51 , 1E011J171fé?1131151 $11311 OE1. ( ep1ga110cateCh1n ga11ate ) EE Egiiﬁﬁ ( Ch10r0ge111c ac1d ) O1O1%% 5F‘ 31E1. 5 555 TG21C1 - 51214 55 5555 11 - X1X1 X1 X14 555 5 55 5 M55 555555555555w555555555555 555~w551555555L55o55L5i 515. 1555X1w1555555va5w554551 EE 5555 55 oO11 551 73 / 1171 * 1 51511 RNA 5555 51X11°11. E11&71E1%O151T91°11511j 555 5E 5555 551 3 9 , 1 : RN151011 / ‘151O11515E 555 55 X§1_X1X1511 , 15 : 1 O11 / ‘1 51O1E5E5 / ‘1O11 55 Z : %51O1 * c1 91211 , 5 51 51O1E5E 5c1O11 - 551 ﬁ%51O1E1 5X11 , E 5555 551 5£E5E1X11§£é1i5 O155X11 , 51.51 51 51°1JE1. 5%1011J5155711519 - 1X11%O19.1 . 55 555 Z151151°1 555 5555 5555. 55 5 ﬂ 1"“ 5 11111 111. ‘£15115. 11> } L1ﬂ o. E 010. 1. 111 W W W 1oO. , 131 1 ; O>< —111111. 13111. ii o1. é. 5. J o_>11. o. - { 1 : : EE , . EE1E$%%®1~>J : E€ —1— ' . 555 : >. 5555 F11. 1>r2r2i19195_0 , 11 } ir$. £1101‘O5. ‘L 11031.13—. 2 1. ' 55 OJOJjL. O. Q A. E 111. F 5. 19 , _O , 5 111111 r>~I _> , : . 5 mm 1 %15 5 5 111. F15 1110 55 £1 110 E 5 11. 5. ( 11b0Zyme ) , RNA1 , E_ 5555555555. F131. WO 2013 / 077617 PCT / KR2012 / 009842. [ 44 ] . [ 45 ] . [ 46 ] . [ 47 ] . [ 48 ] . HH r2 : r1o w ﬂ 0 Mi 3 _> : , @ . E M ii a g oﬂ m M >~. —<1 , ) —%§r. u + 1%1 ) 01 %%%%% D } %ﬂ %% ﬂﬂﬂ M ﬁlﬁE - E - . . . OR. M MM , R - E : wazsm mm mm 0P>C171EE~E114J7<15CL1 M 33 O. 3. , %E } 1 : °E‘ , 1 : 1 + 1 : C2 , H1? } i% , —&13 ] ? } l : % , 11H<% , Ea awmog , ﬂﬂH1? } i% , %U1EOE‘ , UVWE EEE ﬁEﬂ O } %71 %ﬂ OME171O17M , : . , ; i% , %% , $1%o1i ; ; rg , omyr% 333 seC—J1j * Eé7 ] %ﬂ. m$%F=‘£ * EWW. n : % W w W E E g. i. rEijﬂEgﬂm f. m : 93 f. EIng O JO m M MM —L : E mm —h‘ : %. J 10 W E 0h? : L o Q Q 113 O oBi W E r. ﬂﬂﬂ $$$. w @ m 3 ; 1 : 1 m m mm m m _>‘ ; m a : 10 m é E ﬂ g 118 mm m m 2 : E m m. WO 2013 / 077617 PCT / KR2012 / 009842. ﬂﬂmﬁdE%ﬂ%M%Lﬂﬂﬁ%ﬂ%ﬁ%dMﬂa - ; 3 %ﬂ%EﬂQ%ﬂ%qu. $WH. ¢%m ﬂ _1>_4 , m. m. H. W. [ ® ] Eﬂ¢%$ﬂm%ﬂ2ﬁﬁﬁ%1m. ng , 8 } U% , E } ﬂiﬂ%13 : 9 } . m 1 MM 2 009ﬂ %%W ] § 63%ﬂlE 3M E7 } é‘??? ﬁﬁﬁxﬂxﬂﬂ %%%. ﬁﬁﬁﬂﬁﬂ%%%%ﬂE$@1. 3 £ A N O 8 E W ﬂ E W > ﬂ : 10 E W >_ : _ ; 2. %$ﬂW4ﬂ2ﬁﬂﬂ§ ] aq3§L4Eﬂﬂ%% 4_ , 5ﬂ§%Cﬂ 9$a1%?%?EL7 } g&o } gg : ? : §. a. ﬂH$lm - U$ﬂ. 2. H. E WJNHJNw. 1 L. W. mm. § ﬂ ﬁ §§ II olﬂﬁI EE OEoE , M N § ; g + 11% ﬂ iii ; : w W jﬂ iii 0. A g M A oBi % mE V L a W 1>m m A> §§§ % E K ggg Wmﬂ m gg. F W o. m ] Emmq&@%%%¥$ %1%mﬂ : ﬂ%ﬂa%amm%aaq 6. MM Hil oE. é. PHﬂ % M $ W ﬂ ﬂ1m oBi _.>~I_ , E E & J ; H E E H g 3 g 2 W m N W W. mmm. mel oJOL rE. 11$. —H rN W . ﬂﬂ W _\ ' l$ E £ 2. 3 ; . F40. , ' éi$“. m ﬂ W ﬂ. oH0¥. Eoto. W. BH. 3. $. 9. d oE ﬂ - ﬂ. ﬂ%m. ﬂﬂE§¥hmm%ﬂﬂﬁHmN%ﬂ%ﬂ A %%ﬂ%%%%§ﬂﬂWE% @aﬂﬂ%wwmw%%§. 6. ﬂJE W ' E _O. é ﬂ 22%u “ _l%_9L. o31. & é uiE¢mmm ; 2. ﬁoﬂo$ﬂ. mmm% é ﬂ ﬂ MO M iii m g ﬂﬂ fl E E é. A. ﬂ #@. J. _O , . H=. ﬂ. ﬂ. % W. é. %1ﬁﬂiﬁ%ﬂ%$E%d. m ﬂ. ﬁ%J , . BN. ﬂ } § E #rp 111. £m W A. , é. o [ - r1 E rm oE. W%mm“ ﬁ. iii & gj2£“ é . 3 w. _ﬂ mTW ﬂmE M w. r ﬂﬂ % W _l%. E S g oSE w ru [ o _l% E £ 2 a E g . % H m E E 10. o££é¢$ £WEr. w. w. _l%. - —4. a W w £mb o E. E W. i . WJﬁ W0WEm£. ﬁﬁ. wAw ﬂ —1m m3 0 W M m E ﬂ ﬂ E ii W ﬂ w ii ani _0. m. ﬂ% ; E. WO 2013 / 077617 PCT / KR2012 / 009842. [ 54 ] . [ 55 ] . [ 56 ] . [ 57 ] . [ 58 ] . [ 59 ] . [ 60 ] . 61 , ? } ? } $Z1 , 3 } %%X1 , %ﬂﬂ1§2ﬂ3 } % %0 ] * } %% 5r‘ 9 } . CL ] 7L } 3 ' E1?< } O117H waCﬁﬂvE 7% : E W33? & / ‘é%Q %1%l. 2 A iﬂ $5.3 0.0025mg / kg O ] 2 } 0.29 g / kgo1 aa %%% 00 §%L%% a 2 9.1.1 : } . E%2 : %§rE } U1 W11 2 a xﬂxﬂ§H %$ﬂ * ELE : 5mg / kg OVE } 50mg / kg O ] ﬂﬂ §§ ﬂ HoL g %%% ZT : 222110 , %% §—P—1 : — iiXM V Pr 2W1011 WW $981 7H.% ' 5‘ } O% * 8 } ? ﬂ MM _ - — . z : : %%ﬂ %%Hﬂr%%%ﬁ10ﬂw } a } , %ﬂ. ﬂ%?ﬂ ] EEE ﬂ%§i X1 ] ﬂ %9—i ﬂWﬁrgE. 0 iii 91E } . e } 7 ] ‘ﬂ? - ﬂ%?<ﬂlE 0332% ] , 7§3. X1 ] , £EE1 ] 0 ] X1L%%ﬂ , %% , i% , Q C 0 WE. EﬁE%lJr Eﬂjz : %$E } U1UrXﬂ 2 ﬁﬂWE 1 w 1.8 O dd H } %Z1 ' 5 } U% , Brﬂféﬂ§rﬁ9 } 8. ﬂZ : %§rE } U ] 4x11 2 xﬂ X1 ] : 1 1 MM 2000M %%H ] fé 6 * L%EJ—1 : — 33.01 H } %74 WW. ii %% ﬂ H } %2ﬂ§ % 04 ] fé2ﬁ , ‘33% 9%2112119 } EﬁJjZ : %§rE } U1 LW 2 WME ‘ %_. E~ ; & * §% % 7d } . %%oﬂ r218 } o% 0.001 MM 5%%‘t%§ E?M—E ﬁﬁ H } %Z1 * 8 } . E% E - HEWM ﬂﬁﬁ ﬁﬁ %% ﬁﬁﬁ % ; 6Jé% : ' < 3% O11E faﬁOﬂ WW ii %%ﬂ §ﬂ~§ X% ' 5 } / \1717<1%% : — Hé 0 WW ﬂﬂ 94%2ﬂo11CQ1iMi2i * } %% } % 7 + % 0 33 0%1% %% #% / ‘é * él ' ﬂ ; 3.2% ﬁﬁ %% 741ﬁ§EMé 211 ﬁ + §—21 ] , 20 : ; §§xﬂ Hc } l‘%x%1 , } &§ } Hc } X1x%1 2k : 435‘ : %% HH§$€7PE 22 01 7 } % * 8 } F + . EE?? } %ﬂ1ﬂ O } E‘J‘J‘J‘Jlﬂr ﬂﬂﬂ O11. &E. O. : . EE. W E. m ﬂﬂ o ] E ( CeramideS ) % E€—Xﬂ 33% X172‘ ( Lipids ) % ( Hydr0c0rtis0ne ) %ﬂ ﬁEﬂEO ] E ( Ster0ids ) , H a E 333 ] E1 ] O ] E ( Retiny1 pa1mitate ) %% H ] HHA %Eiﬂ EEE / El Eﬂﬂ ] % ( T0c0pher01 ) , 7 ] E } é } %jﬁ%% %% ‘ : 312 ] Q ﬂﬂ E ( 1eCithin ) % O ] %5 } O% 3 E% ( 1ip0s0me ) 333 ﬂfé ‘3%ﬂ Ur N—Z. : E1 ] OLﬁCQ - ﬂO ] E33? ﬂﬂﬂ ( Nstear0y1 - phyt0sphing0sine ) OH E?‘ N ﬂ 33 %E. %%%Q ﬂ?é } iii & / ‘é%ﬂ ﬁﬁﬁ €9ﬂiﬂg§é$ ﬂﬂﬂ %ﬂ1° ﬂ%§~ixﬂ5§% ﬂ$ﬂ%?i31 O1Mﬂﬁ , U ] ‘i‘13L% , E / E O1 ] ‘§ / ‘ﬂ ii %%§ } %5‘n £2l“E‘EL , EL% ﬁﬁﬁ U ] %H1l4r %°~.ﬂ‘ %‘F O * %§ } €E— } * F ‘61 ] EE ééﬂWZﬂ. WO 2013 / 077617 PCT / KR2012 / 009842. [ 61 ] . [ 62 ] . [ 63 ] . [ 64 ] [ 65 ] [ 66 ] . [ 67 ] . 2 WA A m r1o it A A A oBi A W A W. 33 % iii L W ﬂ oEL E A A m. oi W oZ : mm W. 0 : 10 10 mm A R m oE : A E W A om 112$ A M m E E W A A. AA. A érlT oﬂLT - LIV [ . A 11$ W W m. A. A @. E. A. oEi. Mo. A. m. % ; L , : 2 4>. 3 m2 0 A g E - l> E g W W - { 1I m A W. N i E A w. A HHﬂ EA AA - l1IE 33. m f m \mEJEL M m$1>J>i£ 33 ii 01E 1111 , . w a oZ : W HHH m m A - l11‘1 - Q EEE om A A A. A. m. 0b. A Q4. 0 33. iii % E Q g A W om U9 031. 0 Mo m M M0. .£%W ' E m. % E 1— ' Mo A r_> : . g H A E w m m % _l_ , A A A g 33 11$ A ﬂ E A — [ m oZ : . ﬂ >. g m % EE 1110 1 o W oZi A A oEE 0%0 - 1m ii. A. oZL A OlF JR HH. ﬂ oE , $ A ii W 33 r g R g 0 - H W W A m mm W. ﬂWﬂ$A ' ll m , A. W n11o _1> ii 0 2 g 0%0. Ol J ﬂﬂ - P 5 - %h >< m - 11 W =10 W W 0% E E. W E W A JW ﬂ. A A m g A E M H g m A. A. ¥u. m111 E JE W 40. v oE E V A [ m 0 rd oBL. 1.1 §§ 111E ‘3% HJ%. 8%% Q $73‘ NC / Nga U } —‘ : | * : : * E ShiZu0ka Lab0rat0ry Anima1 Center ( Hamamatsu , Japan ) OH H 31% ] 5 } ?“4. %$i * } H% Sigma - Aidrich C0. ( St. L0uis , MO ) , EELiﬂPrﬂFK - SO6 ) Q * } O1§§z : : ; i_%—8— %%%%% ﬁl ' ﬁﬁW * } % * 5 } 2i1 : } . Df b0dy ﬂ F7 11E Bi0stir InC. ( K0be , Japan ) O1 ] H %W 3 } 9iE } . NC / Nga U } ~% * Z : OH H OHET % %E€3 } 7 ] % ' 5 } O% , U } % : : Q gg ﬁﬁ ﬂﬂ 33 - 1 } H O1 ] 4% SDS ( s0dium d0deCy1su1fate ) % 54 a ' 53 } ?5i9 } q 3 * ] 7& ' 6F3 Df b0dy Odﬂ~§ EE ' 5 } E§\D } . O ] 13%?3“ 31 } ?§§% 43V %% 2Hd”‘é1 ‘1&3 ' 5Riq. 541"? 33 %% %% ﬂﬂ 3d3r : ( CliniCa1 Skin sc0re ) % O ] % ' 5 } O% 3 : } ?f5T9iD } . %% V 3% j§§3f1 ( c1inical skin sc0re ) lE %% / %€§_ ( erythemafhemmrhage ) , %E1 / Zjé§ ( scarring / dryness ) , 3%? ( edema ) Q 5% ﬂ } & } / 31311§ ( eXCOriati0n / er0si0n ) %%% 7 ] ii ﬂﬂ 0 ( n0ne ) ~ 8 ( seVere ) £.§ @$%HﬁL1@$%%&ﬂﬁ%%ﬂﬁd. ﬁﬁ ﬁxﬂzﬂQJrTGz WWW ErEw %% waOM ﬁﬁﬁ %% W‘? 2&4??? w u } %3 ; % * } % * 8 } S2i2u% , NC / Nga U } %Aﬂ Df - %E% “ %%% * } % ' 3 } 0% dqu 71w. AAA 21ﬂ6 } 9iﬂr. J. . . WO 2013 / 077617 PCT / KR2012 / 009842. [ 68 ] . [ 69 ] 1.2 ﬁﬁ ﬁﬁﬁﬁ TG2‘— * ] 7ﬂ ] ?<1 ] q EE EEE %% 1%OE1011943J ° } E3ﬂ 7H4ﬂ iii ﬂﬂ. [ m ] ﬁﬁﬁﬂﬁﬂﬂﬂiﬂ%ﬁMWEﬁ2gﬁth2%ﬂﬂﬂ%$ﬂ4@ﬂ 5%? ﬁﬁ d a 8i EEE 21% } 71 %% ﬁﬁ %$ﬂ * } E1% 33r - %% 8 } $d1 ﬂﬂ %?ﬁ£EﬂﬂEﬂ%ﬁEE%WEE2gENHE%E%§%aﬁ $@a%dJ%E%w&E2§w9%@%&ﬂ$ﬁ8§2ﬁZHH : l%% $4€hﬂUk%ﬁﬁ£%b§ﬂ2$4. [ 71 ] . [ n ] : mJ%§%ﬂﬂ%%$iMﬂ%%$dw9WPw%ﬂ$@$mE. [ 73 ] E } £13 : El%1z : 9 } é%i%31A } ?19l * §~% - Ei¢1§ : i4. [ 74 ] % * Erﬂ * } ‘%1—9 : 500mg / kg / dayf ' a , ﬂﬂEﬂ 511 : : - E O } E§J 7? ] E Q 04 ] % iiﬂ - E %%%%%%%Lm%@me$da§qgg%ymp } ﬂﬂféfﬂ~$£2 ( FK - 506 ) % %% EE 33 % E i % OEBJ aaa NC / Nga ﬂ%ﬁﬂHﬂ%%M$%@$%§ﬂﬂ%d. [ 75 ] 7%31 } % E 1 E E 201 ] UrEMJ ‘2113a. mm : £N2Ezﬂ4ﬂﬂHw%9%%%%%H¥ﬂﬂﬂiﬂ%i$Km@ﬂ%% - ﬁﬁ % : L%o1 %$a / + E1 EH51 555 a §1§l$‘ﬁ ( FK - 506 ) Erli : 1E4ﬁEﬁB } %%ﬂ%%¢§%%ﬁﬂ%%ﬂ1$%ﬂﬂ%%NﬁﬂﬂEﬁ%§ﬂ§# ﬂﬁq. [ 77 ] . [ 78 ] * } 01%%3 : £ : 3E§13 + é%i%3iA } ?19l * § - % - %i¢1 : : 34. [ 79 ] * } 0 ] %§_¥ : E% ( CsA 10 , 45 , 100 mg / kg / day % * Erﬂ ) \ } ‘?l 100 , 500 mg / kg / day% I$%E%%%$ﬁﬂﬂ£W$?&%%%%N0mg%ﬂﬂHﬂ&§ﬂ%%M } ﬂ¥@$%%ﬂQﬂa“d. [ m ] §ﬂ%E3w ﬂﬂﬂﬂ. [ & ] Eymqﬂﬂmﬂ%¥L&ﬂ§§ﬁE%ﬁ%%%Hm®@WWﬂﬂE §ﬂ7 } 1%” ) 7W1 9%‘?i9 - Ur %$i * } ‘§ﬂ 100 mg / kg / day% 33 %—Ero : 1 ﬂﬂ %% Q §ﬂ7 } EEEE 33% Q?_.6EL ff ﬂﬂ 93? } % * Erﬂ * } ‘?l% 500mg / kg / day %%£. i %%$ﬁ&ﬂ%ﬂ%i£E%&%%%ﬂ%mﬂym%HwHWhﬂ%%ﬂ mm%mwwE%ﬂ%NﬂﬂH@HE%%ﬂi§ﬂ%%ﬂW%ﬁ%@HEl <?%ﬂd. [ & ] ﬂﬁ%§ﬂwHRh%$aMﬂ%mmg@mw%%g : 3@%§l 4ﬂ%EﬁE%%ziHm@@mMﬂﬁ%%2§%wﬁ$ﬂ§§ﬂ% 4ﬂmEﬂ%%ﬁHb$ﬁ%%ﬂ§ﬂﬂﬁ%. [ % ] EEEE4ﬂ%ﬂWﬁd. [ 84 ] E : 4ﬁﬂ L + E + %ﬂtﬂ4ﬂ - %%0 ] , A } o ] %%3 : z : ; §E1 1ngnqyday?1 ; ﬁé%€%51§ : . L%2 $@aqE%$ﬂ&ﬂﬂ%%$ﬁNMﬂ%EﬁE%@%Hm%MwW%. 11. WO 2013 / 077617 PCT / KR2012 / 009842. [ 85 ] [ 86 ] [ 87 ] . [ 88 ] [ 89 ] [ 90 ] . [ 91 ] [ 92 ] . [ 93 ] [ 94 ] [ 95 ] . [ 96 ] [ 97 ] . [ 98 ] [ 99 ] . [ 100 ] [ 101 ] . @%$d@@%ﬁd. W. % §ﬂ§4 L + 9r14 [ 9i?. : m2ﬁ§ﬁﬂﬂﬂéﬁ%vWU%%$@ﬂQ@%WE3HN%ﬂEﬂﬂﬂﬂ. ﬁﬁﬁﬂﬂ%Hﬂﬁﬂﬂﬂ%$ﬂ%H%E%ﬂE&%%$ﬁﬂﬂ% - * } 9 [ Eﬂ?l g ﬂEﬂﬂ %H [ %kg %§P§‘ : 9 } ?l5 [ 7 ] 948 [ O% , 33% ErCﬂ 1%% 7§ﬂ ~19 : H ] 3 ; , L2i3i - E1 ﬁE - E Oéﬂ 0 [ % PMA ( Ph0rb01 12—Myristate 13—ACetate , sigma ) Q MMQ O [ $i140 ] 44 ( Ca1bi0chem , La J011a , CA , USA ) OH H 37°C , 5% CO2 o1 ] H MM Zl %% HH Ookﬁgiﬂ. HH Oo ] : %%%% Ei - E - $IL—4 , 1L—5 , 1L—13 , 1FN - y , CCL17 / rARCﬂ lgEsa } o ] g%ﬂ ( eotaxin ) % ELISA 7 ] E ( R&D System , Minneap01is , Minnes0ta , USA ) §i * [ % ' 5 [ 9% %% ' 5 } 3§. E [ . ﬂﬂEﬂ3 - ZﬂFK - 506ﬂ } %§r : aw¥1 a 33 % wioi 331 } . F / [ ELEE ' J~‘1j : / E ( FK - 5O6 ) 1.0mg / kg / day9 [ %—Erii / \ [ ‘¥l 500mg / kg / day% %% EEE 33% $<ﬂ iii é UHLzﬂ H ] % HEE - O [ %€ : [ O% 1L—5 , IL—13 , O [ 9_E%é1 ( eotaxin ) Q TARC% EEEE 8% ELISA 339% 553 agar } , . €31P§ E 5 MM E 801 [ UrEWWier. E 5 MM E M ﬂﬂﬂﬂ HM %O [ , L—5 ( E5 ) , IL—13 ( E6 ) , TARC ( E 7 ) Q O [ $§ ] } 1ﬂ ( e0taXin ) ( E 8M %% 0 [ %$a / \Wl BBB EEL§aPr¢~§ %%9_§ $9 ii %% ( p=0.008 1 ; ; p=0.011 ) EE~E - &E ( p=0.001 ) 1 - 11 : [ %$a / \P¥lﬂ ﬂaiﬂlﬂrﬁS - 33% $96 —1 : — %% EF% * 5‘ [ 7 [ [ Z [ ‘8HE [ ~E 33% QQQ é? 9. } .9ﬁ. t : [ . E%“ %§ra / \ [ EM 33%wE4ﬂ : w } . E%<CsA ) 2. 5. 10mg / kg / day X1%%‘tﬂ %§rﬂ * [ 1¥l 500mg / kg / day%. EE BBB %% ﬁﬁ Q i U [ 5rZ : ﬂ HPé } H [ : 5i_—§ : O [ %—‘5 [ O% IL—5 , IL—13 , 9. E%r ) d ( eotaxin ) , TARC %% TSLPﬂ ng / t §ﬂ% Hmﬁmid. 7§34~§ E M L + E [ H [ 9P4. E M ﬂﬂﬂﬂ HH €0L Z [ %%E5% * [ 0 [ §féz : £%ﬂ [ %§rﬂ / \ [ E1 33%wE—O% / \ [ 2 mg / kg / day %%% E§j¥t$l Elé %%o1 [ H Th2 AM Eﬂﬂ ﬂ IL—4 , IL - 5 , 1L—133l [ ﬂﬂﬂﬂﬂ O [ .9_E , ML1 , 3. W31 1% %§rﬂ * [ ‘¥l% EEEE i [ E§ [ EOﬂ m 8M %%%. "I_. ZaLZtE‘ iii‘?. 1.2.3 ﬁﬁﬁﬁﬁﬁ %—1€ - Eﬂ / \P¥1 ‘33% $04°119I§l T ﬁE - ‘ﬂ ﬁ@%&ﬂ§ } § [ a ﬂﬂ HIE. EEEEJPrﬂFK - soéM %$aw¥1 : ﬂ 33 % ﬁﬁ : éw } . %z§% CD3 + W33 1 ; ; CLA + H15J~EQ %%% OLEJJJ §§J~§ ﬂﬂ O [ O [ %O11 H EFEﬁ - cﬂﬂ ] %7 [ L : 4 l. : — ZULE ﬁﬁﬁ Oi 9lE [ . NC / Nga ﬂ oM Df—19rE% CLA + g CD3 + WE EEﬂOﬂ éWHfiE ENM %%Oﬂ ﬁﬁ 94211 ﬂ ﬂ. 12. WO 2013 / 077617 PCT / KR2012 / 009842. [ 102 ] [ 103 ] . [ 104 ] [ 105 ] [ 106 ] . [ 107 ] [ 108 ] . r1 ; . 0 ] %‘5 ] O ] 3.78 Niiflu ] 50mﬂ 7%33% Oéﬂﬂr. ﬁﬁiF % X ] ] 7 ] ‘5 ] V %—8— 100 mM * ] E§_”&?§ %%% ( pH 6.0 ) o1v ] 5% } 888 7 ] O§6 ] 8i1 : ] . W8 1 g L%% 3% BSA ( b0Vine serum a1bumin ) O ] ] 4 ] 1 * ] 3 P59 } §%9_E 95t8 ﬁﬂ , ﬁﬁﬁ iii 1 : 100 anti - CD3 7%58 ] ( rabbit p01yc10na1 , abeam , Cambridge , UK ) Egsns anti—CLA 92 , ] ?8 ] ( rat m0n0C10na1 , NOVU. S Bi010gica1s , Litt1et0n , CO , UsA ) 2 ] 4°Co1 ] 8 ] * 8 ] 5E : 1%%31 ‘$18818114. : a 31 CD3 88 48 - 8 ] 8H A1eXa F1u0r - 1abe1ed g0at antirabbit IgG ( 594 ; InVitr0gen , Eugene , OR , USA ) EEE CLA CE 444% ~84 ‘3H A1eXa F1u0r - 1abe1ed g0at anti - rat IgG Q IgM ( 488 ; InVitr0gen ) % 1 * ] 7L } %% ggg 8 ] 1318 - 8 33.14. 111 % H0echst 33258 ( Sigma - A1drieh ) E m H ] 88 44 ' 5 ] 93 , ] 3 ] . 88 g E : éE ] % %% image ana1ysis system ( Dp Manager 1 r 2.1 ; O1ympus Optiea1 C0. , T01<y0 , Japan ) O ] ] Q ﬂﬂ ‘ET / 34 ' 5 ] ?3i‘3 ] . EEEE J1 : ' 2 / : ( 1 : K - 506 ) 1.0mg / kg / day9 ] %$i * ] E1 500mg / kg / day% %% EE 8 8 88 ii : 31 , NC / Nga 8 on 8 ] Df—%E% CLA + 88 CD3 + WE EE o1 ] £933E ENM %€% E } 7 ] 9 ] 7 ] —E + aaaaa aaaaa 7.34% E 10o ] 444 81E ] . E 10o1 ] UrEHH 44 7E‘ * O ] , %§r : Ti / ~ ] E13l ] EELféﬂPr 1 : ] —~% E475 ] 2E CLA + Q CD3 + TK ] ] E7 ] H 8 - H %% Qﬂ8 ] 9jE ] , . _ [ >~l rL H. 88 i a. H. . : | : ' 4. * ] 0 ] %§£E%ﬂ %$ﬂ * ] ﬂﬂ 888 —ErCﬁ iii ] . ﬁﬁ 7 ] 15‘% EE5§“5‘ ] - E 3E7§ T 4 ] ] E ( regu1at0ry T ce11 ; Treg ) ﬂ $9 ] 7 ] O ] E‘5 ] T ] ~1‘%?§ °1 ] 4 ] 7< ] ‘5 ] ﬂ—1f iiii %E ] 7< ] ggg O ] 3 ] ?1 §~J§ T ﬁﬁﬁﬁ X ‘5H? OHEB? ‘ﬂlWﬁ %7< ] O ] ] * ] Th2 %°—dﬂ§‘l * 8 - ° ] 8 * * ] ] §‘1 ﬁﬁ EEEE 2 : } H ] %— iErO ] ‘813 ] . [ LHV ] * ] O ] i§‘fé : ‘ : _%%ﬂ %§rﬂ / \ ] E1% 8888 —ErO ] 3 E 78 HGE $$ ﬁﬁﬁ §31179 + iii ‘Qﬁ Uri ; X1 0 ] l‘i - % §ﬂﬂ§§ﬂn H ] ?é } / ~ ] ] E %ﬂ ] 8 %% 8 ] ] : 3i.% FITC - anti—CD4 ( GK1.5 ) iii PE—anti—CD25 ( 280406 ) ( R&D System , Minneap01is , Minnes0ta , USA ) ‘% 9 ] %‘5 ] O ] 88 9% ] “5 ] 9siE ] . % 444 E W 333 PBS , 2% FBS , 4°C ﬂﬂﬂ 81 / g1 O1 ] 8 30% %% HH 888 ] 8i1ﬂr. HH ‘8% 81 ] _%E% 2a ] . 4 ] ] 731 88 * 8‘ , Ce11Quest s0ftWare ( Beet0n Diekins0n ) % O ] % ' 5 ] O ] T 4 ] ] E 5F‘ch ﬁ§ aaa%4. 7.334% - E 11a ] 444 8 , 114. E 1101 ] UrEHi ] 44 7E ] O ] . X ] ~8~%Fﬂ * ] O ] §§ﬁE% ( CsA ) ( 2 , 5 , 10mg / kg / day ) . %§ri / \ ] Eﬂ 500mg / kg / day% 8 888 * 8 ] —E 7§£| ) ‘ , 7 ] ?8 akE - i - %%ﬂ 2. mg / kg / day 888 E%1 * 8.1 EE 8888 CD4 + CD25 + &?§ T 81 ] 3i.—r - 7 ] msZiLOL 8 ] . , E1 ' 8V ] 888 $8 %% * ] O ] %§£ : E% %% 88 %—Erﬂ / \ ] E1—8— %%52§. : 10 : 10 L OW a 01 W E. 13. WO 2013 / 077617 PCT / KR2012 / 009842. [ 109 ] [ 110 ] . [ 111 ] . [ 112 ] [ 113 ] [ 114 ] . [ 115 ] [ 116 ] . [ 117 ] [ 118 ] [ 119 ] . [ 120 ] . [ 121 ] . [ 122 ] . [ 123 ] . [ 124 ] . [ 125 ] [ 126 ] . j ] _§_§l - 88 u ] 818E8817 : 88 888 88 88888. 1~24895191X111119188i181888881481H1”1 / 11 ] E8 : } ~18zj¢ 88 88. m * 11E188. 88888111188118 8 8888 8888888888 888811X1 ] 888ﬁ118188888711188881188 88888 8888 8 888 o 8888 8 a1 888 8 H 8 o1 O 88 8888 888 E E$ddE8UmmmMmWQfT7ﬂC@m@m®Ewm8@qXE§. TlE * 1 ] : 4E m E EEE f1Ve h1gh - p0Wer f1e1ds ( X 400 ) l? ; 8888198 1JrE1141$3q U1. 88888 : ( FK 506 ) 8 E88888 88 88 8 + 1. 88888 Z : ( FK - 506 ) 1. 0mg / kg / day91E 88 881111 500mg / kg / day8 88 88 88 8881 8 NC / Nga88888 / 111E 8 8 88888 88 888 88 888 88888881 : 888H1ﬂ888. 888E128E13o1188888. E 12 8 E 1381 888 88 88 88 88 8 81 : 88888 88 E13.18Eﬂ~8&_ ( FK 506 ) 8 E 885 : 8 88 8 8 : 7§% ( P 0. 003E 8 P=0. 002 ) _HE8 %—Er : ﬂ / \1U18 88888 : ( FK 506 ) 8 88 8881 88 8881 : 71i 8 1118141‘ : 8 8 88 o18111 ( 88_8 88 : ‘ : P P.=0 0.01 ) . . 8888888 888888 88 88 88 8888888 10mg / kg / day 8888 888 18.81 500mg / kg / day8 88 88 88 888 8. 88 888 888 8888 8 888 88 88888. E 1 ; 8E —$1 4> éé 33 12 88 ll £E ' 10 ' 8 2 ; 0 WW 0“ 1H , 8 E 88 5 8 33 E1 ; . 0 <1 8888 u 888 8 88888 M 88. 88888£8 Z174 88 8888 11 88 88 88 88 88 111 IgE8 111 11 8 Equpagr 4%8o1 1%?E10 888 88 1 : 184 : 13 888 88.9.8 , ELISA 1<1t ( Yamasa , T01<y0 , . ' [ apan ) ‘—E~T_O 8888 % IgEvC8 888 88 513iE1. 8 E15ﬂ ] %EbHAﬂ4 - E 1581 888 88 88 8 88 1gE8818 888 L 88 88 O 8 888 88 ( p= 0. 002 8 p=0. 003 ) 814 888 7E1Zc~8 888 Z174. 14. WO 2013 / 077617 PCT / KR2012 / 009842. [ 127 ] [ 128 ] . [ 129 ] . [ 130 ] [ 131 ] . [ 132 ] [ 133 ] . [ 134 ] . E .1 E 888 88 8888 88 88888 o111a1 88 8888 8 IgE8 888 88888 , 8 888 88 8 x11 8 888888 8888888 8 H1 88 888 888 8888 88 888 8. 1.2.6 * 1° ] %EZ : E%3L1 %$‘3i / ‘1‘¥1 88 88 8 ] Q 88 888i% ( InV0lucrin ) 8 8818 ( ﬁ1aggrin ) 88 871. 888 888 888 88 888 8 888 8 888. 01 88 88 888 888 8 88 8111388 88 88 88 88EL8 88 888 8888 / 1118818 88 88 888E188 888 8.9.8 8888. 8131 * ] . * 1O ] %§&_E88 888888 88 888 88 8818 88 888888 88 888 88 893.131. 883 : 8 %388E1 88 8 88888 —80OC81 / 11 88888 O ] 86r , * 1 ] EE il§§1 ' 5131 Lysis buffer ( 10mM Tﬁs - HC1e0ntain1ng50mM NaC1 , 50111M NaF , 10mM EDTA , 1111M DTT , 1% Tr1t0n X - 100 , 0.1% SDS , 1%s0d1um de0Xych01ate , 1 111M pheny1methy1su1f0ny1 ﬂu0ride ( PMSF ) , 5111M 1eupeptin , and 10g / m1 apr0tini11 , pH 7.5 ) O11 888 ] ] M 332.131. 2011g 88888 Ookq E81 888 10% SDSp01yacry1amide ge1 e1ectr0ph0res1s ( SDS—PAGE ) E 88 ‘5131 , NC 11101 ] 88888 888 8888 8 , 88 : 8 , 888E18 8 8888 88 8 ( santa Cruz , CA , USA ) 8 ] 8 8 1 : 1000 8 8 888 O1 888 1$l1 * 8 - ( i11eub211ti0n ) } ‘ ] 333.14. HRP 78% 9 ] i1§ } 5<1 ] ( 1 : 3 , 000 8 91 ) % 9 ] % ' 51O1 %7178 iii 8 ] ‘2 } 81 8 %%319.19_F8 , ECL P1usTM Western B10tt1ng Deteet10n Reagents ( Amersham , PiseataWay , NJ , USA ) % O ] %51O1 M Z1§1€3193\1 : 1. 888 41 : 85 : Image Reader ( LAS - 3000 ; Fuji Ph0t0 Fi1m , T0ky0 , J apan ) % O ] %‘31O1 88888. 734 8 E 168 88888. E1681 888 88 8101 , 8888 8888888 ( CsA ) ( 10mg / kg / day ) 8 %8Eri / \1‘?_1 ( 500mg / kg / day ) %%E1‘O1 ] ‘ ] . ﬂE8ErEL% ( InV01uer1n ) Q 13111 : L% ( fﬂaggrin ) 8888 888 8 888 8888 8 88 8888 88 88888. 88812.01E8 888 88888 88881818TG28Z1111188888 88. 1118 O 8 18 8 W 111 4n 8 3 ; EE : 12 8 11> 91 W >8 4 1110 88 r 0 ii 88. 15. WO 2013 / 077617 PCT / KR2012 / 009842. [ 135 ] [ 136 ] [ 137 ] . [ 138 ] [ 139 ] . 2.1 %%§€§ - sC0RAD XV? A } o1—§— : zg% E g m } : — % oH : X ] X3%%%E9ﬂ ﬁﬁﬁﬂWCﬂA E a , a ( 500mg ) 3l } 33%‘5W 2% , 14A ] EE 2% , 33 %‘8 } 0% ﬁﬁ $<ﬁ ﬂﬂ SCORAD 21”% { 3 - 23 6 } ‘21ﬂr. * } O1%§ : : ~£%—& $o%%%hq g o 150mg ( Cs1.5 ) BBB 200mg ( CS2 ) % o ] % - 3 } Sii1 : } . ﬁﬁ ﬁﬁ $4 N E OM SCORAD ﬂir - g - % : <g a } 9gu } , SCORAD z ] _2 [ ~. ; : _ r , . E m m w w. % %% EEE %% ( erythema ) , l. j - —7 : § / 317ﬂiii ( edema / p111pu1r : 1tior1 ) , %% / 7 } ﬂ ( 00zing / crusts ) , 5% } 5HeXc0riati0nS ) , ﬂ ﬁﬁ ( 1icheniﬁcati0n ) , ‘ﬂldr / Tdaskin drynessM 6%¥%3i LJrl4ro1 m } 23.1 ; 3 0 - 393 ; wqu %%% ( 0 - 18 ) X 7 / 2~§— 1381 } mm SCORADEQ WW 2AT‘ : — %%% ﬂﬂ $1 } zr - g / gng - 7% ana10g sCa1eE O - 1O77 } X ] 33 %%Z# SCORADQ %%L ( 0 - 103 ) 9_i 74 ] &§ } U } ( Eur0pean TaSk F0rCe 0n At0pic Dermatitis , 1993 ) . : 13 Ur Q X“ %7< } @ ] 71 ] ﬂﬂ %iﬂr $FE / QOH O11 ﬂfi } X } 7— } % - e } % 0 - 10ﬂ sca1ei 3% ﬂﬂﬂﬂ ‘5 } 3i% W ﬂﬂﬂ ‘5 } 71O1 ﬁﬁﬁ %%% ‘1%017§€§‘5 } %iﬂ §ﬁH331llZﬂ ﬂ EEE ﬁﬁﬁ 111 EM ﬂ SCORAD Z1— / FE } E§% - 5M 0—83 a 3E 5% 7% } 713 aaa ( KunZ % , Dermat010gy 1997 ; 195 : 10—19 ) , 33 § } ‘ ] 04 ] OH H% ﬂ %@ ﬂ SCORAD X ] ?E { } 2_E 3% 7 } % } 3i1 : } . €31P§ E 17O1 ] UrEW 21E } . E 17O1 ] UrEHH ﬂﬂ 7. : l01 , OLFJJ ‘J43i - CE. iiXW ] %§rﬁ1 / + ‘¥l EE $Oﬁﬂr 7J ( 11%10%~11%24% ) o11l : SCORADOH ﬁﬁﬁ ﬂﬂ ﬂﬂd. : Lawr , o ] %E£ : E%j %$ﬂ / + E1% Hg % ﬁﬁ 6 } X } sC0RAD7 } 72.5o11 / \i 51.5§ a a 5%OMiB } . %% %% ( 12%9%l ) EE i543 } SCORAD7 } AM gggggg % ( 12%18OE‘ ) %% 3 * % 133% ﬁﬁ ( 12%30%l ) Oﬂ ﬂﬂ %0 } §iE } . O1O1 * i , E } / \ ] Tﬁ ' cﬂX } O12ﬂ ﬂﬁOﬂ ﬂﬂﬂ %0 } Z£§£j sC0RAD7 } ﬂﬂ %E } 7 } H %% QQ ' 3 } %i1jr. EE WE iiXWW ii A } o1% : z : : si_% %% E 71714 } ( 11%17%~12—%1% ) oﬂl§ SCORADOﬂ ﬂﬂ %§ } 7 } ‘31%.9ﬁ , O ] ﬁﬁ 7gﬂ—1 : — Cgldr 7Hﬂ1 - E * } O1% : ¢ : ~£%E Q %?<1 %%B } —E 71%54 EEE %%% 6&B } . * } O1%E! : E%ﬂ %$ﬂ * } ‘¥l% 33% $0% ii 7L1 } ( 12%1%l~12%15°g ) oﬂ% SCORAD7 } 41o1W 34f ; EE 81 %O } Z$i1 : } . ﬂﬂ * } 0 ] %§ﬁE%% EE ( 12%15OE1 ) $<ﬁ 73H } 9.8 ] a SCORAD7 } %a } ; } : ; 1 , Hg % ﬁﬁ ( 12%30C2M1 Q 811 sC0RAD7 } %%%% é , %§rs—1 / \ } E1 %% wadl : ﬂﬂ §31 } 7 } U1~§ : ‘5 } 2iﬂ , * } O1%iﬁ3€% EE —ErCﬂ - E 7§%Oﬂ W13 } SC0RAD7 } %O } X1T‘ : - , % ﬂﬂ iiﬂﬂ ﬁﬁﬂlE %%% 3311 : } ; 01 ] www * } 01%Ez : §£%‘7 %—Eri / \P¥M %% E E - %$ 4?1 33% : - * } O ] %f ; .€ : ‘. 1% ﬁﬁ on mm m m7 } %—r—% } %i31 , %% 0% ] A } o1% : ¢ ; %q. 71 A } % g. TiT 401%E / ‘Ea - g - %% ( 1%9%l ) E. #14. FF. w ﬂ. mm. WO 2013 / 077617 PCT / KR2012 / 009842. [ 140 ] . [ 141 ] 2.222°1QiéEQ QQQQQQ QQQQ 21 62% 102891 QQQ 62216112191 SCORAD 212F - QQ. [ 1421261 1Q62QQ2Q2Q21QQQ E612 61E61 222222 2126 : 61Q 1 : 1 QQ Q2292 2122~Q iii QQ6271 22 : 202 O2lEJJ2 Q22 10172 QQQ2266 QQ 62O2 SCORAD 21222Q T72629262Q71Q 2222 6222722166 2TQ QQQ T31 2O1Q 6ﬁEQ QQ TO292 221ﬂQﬁQQ62 QQQQQQ. 22222 Q QQQQ SCORAD 21TQ QQQ 2022611 Q22 2222 61O2r2. O ' ELEﬁiE ' JJ * 1% 32C 2— 2.9mg / kg / day , 5§ ; 1%L 2.4mg / kg / day 03l1. ; T ; Q21QQ 22T ‘7 ‘T 2201 : 92 QQ1 , 000mg / day QQQ 222 500mg / dayQ 62 , 2262. 10122Q QQQ SCORAD 21T - Q QQQ 62L2Q 161216 QQQQ 222 QTi22QQ 2201QQ¢QQQ 2222 QQQ Q21 216262 QQQ ( SEQ1 ) 5122Q SCORAD 21T 6 QQ 22 - 1 21O1QQ£2EQ QQQ Q21 2161162 Q22Q ( SEQO ) 5122Q SCORAD 2122 QQQ QQ62° 2. f2. [ 143 ] QQQ E 18611 QQQQ 1 : 2. [ 144 ] E 18611 QQQ 12292 QO1 21Q611 SCORAD 21T72 504 Q Q2272 2201Q6672£Q62 QQQQQQ 22222 QQ Q 38. 477221 H1622 72O U2 , 1 : 221. 1 , 12 , ; 0133. 111_ , . 40 15§§ﬁ£%1 { 2—%E 612 , 1 : 1L2 48.4Q Q627231 QQQQ QQ 21 37.466 Q 62 QQ QQQ 22 212262. QQ Q2223 222222 SCORAD 21T72 68.4 2222. 2161Q626Q2Q2Q2QQQ222Q6q2222mmmD222 %.5QQQQ 2€M672212622626Q2QQT2 222. 2 ‘ﬂQ19ngL1 , / R1O1%iﬁ§%31%EEri * 1U1vq‘213%T°1TETZ‘ : E1E : 1 6“H£22QQ¢QQQQ - T6Qu22222QQQQ wQ $iA1E1£L 1 : 123. Eo23ﬂH l : 1€ A1.1 : I11 ; 1—E_ 111 : } ; . } %. E L ETi 1_ ' —1TL—L. \1 ﬂﬂ. >. QQQ QQQ 261Q 261Q 2622 : ‘2. 1111o. 11121 >4. A. 1>7 m 121~1 1111. ﬂ Q3 11 Q. 1111111129 , 1111 ) “. 1101 L Q - 10 2 Q 1o _O , 111111 E —111 mm m E 1101 Q 10 W 3 E. [ 145 ] 2271 1022Q 22222 222222 222222 m. 1 : 1 : 1o1i1. O%F2J EW : Q% 11er 226202‘ ; 1111 %12 121a 1111 - 0275 QQ 111622 QQ 1111111r 2112i EO £6.12? iii £F1F r§ : 9_1 : i _ [ \1 120 oELO w r_> : . 1111C } 2. [ 1461 2201QQ_7 : 2 QQ QQQ 22261§61 22261 QQ __. A 22 ii Q 33 Q 2 Q Q 1r >< S Q 8 Q Q 8 E Q m 22 3. 17. WO 2013 / 077617 PCT / KR2012 / 009842. [ 147 ] [ 148 ] . [ 149 ] [ 150 ] . [ 151 ] . [ 152 ] [ 153 ] . [ 154 ] [ 155 ] [ 156 ] . [ 157 ] [ 158 ] . o [ ﬂ r1o 11191 0111 00 m E. $01513i% %%7‘<1%3O‘ 711319. : E : %71—a131 %u , _1 55501 ] ; . 394°“ 5 * 1 ‘ mm mm Pr 712104u1E1o1. W81O1 J7 ] 7%31 ] §— ﬁﬁﬁ 93.31 , O ] §— E7 ] f1 , ; A1o1§§5§g%oﬂ % * Er3l * ] ‘1jl—% a. g 44 0 7.594 44 0%1 <objective. g 111% W. Si 0 1. $. 0 _O‘L it 1111 —1m. 111. >. i 55 functi0na1 Va1ue ; OFV ) % 71 ] ) £15 ] 9. A ‘3 ] . EEE E 20o11 444 iiiB1. E 20o11 UrEWl H191 7. : 101.7—17—1 631.64O3l1 653.15354 51% °éS2iE1 Pr 71154 parameter°11 / ‘1 EE %1—r - %.101 5.99 01 221 i1O1UrUﬂ : p—Va1ue < 0.0571 E1 EH1 1%1 %371 ggg 21o171 21.5%13 E1 EE o11. : — p—Va1ue < 0.05 % ‘3% ; ‘81O1 %§r31 / \11¥l3l1?4 111%O1 1%74 %% %%o11 H1 ' 51O1 %% EEE 444 91%% %%$1 811%‘.2Wr. 2.3 * 1°1%E£ : E%3~1 %$i * ‘1‘¥_ﬂ %% - ‘1E - °1 °11 111% °1EYL1 %7<1°1V~191 33 13 * ; 94 ﬂﬂ. EOE. : I E 11 , 3505 812if1m517ﬂ 555 21%1l : 4% m1 wa ; * 23 1. O j { r—§1‘5‘171 00 mg : 25 / 516121 g z wwng 4.2% a10.2\1z1%og 0m &E.—§ <025 - a171 %Z1 * 8 22 61%iD1. mm %% E M 55% w $9. : 9 ; mm ; %o1 - 6171 - 51s22u1. IFN v %% * 101E?1‘ﬂ% i311 % RT—PCR Ho 2 %7<c1 ' 519§.111. 7%3115é - E 22 2 E 23 1 11E1111?i1 : 1. E 22011 11E1L111 H191 £101 %$ﬂ * 1ﬂ Q * 1O ] %ii : _%%% 41% $O1 ' 81l5 %%1L—4 , 1L—5 , 1FN - 0 , 1FN - y %% * 101E?1<ﬂ Oc1C>1 11£61S2ir1 ETa1 mm %%% 1 m% $O1°11 ﬂﬂ %?<1‘51711Z.1i‘319i9ﬁ1.%17<11° 7§9r<>11—EIL—5ﬂ %%% EO11 5 711 115t819i1ﬂr. 338.1 E 23O11 11E11d1 H191 { #301 %§r : 3i * 11¥l311 A. 18. WO 2013 / 077617 PCT / KR2012 / 009842. . . . [ 159 ] [ 160 ] @1 011 3. 91 { 1% 111413i 6.1 Z1794 : $91 56> ; E 711 / 36 [ 161 ] 111% 111 / 619f : gg 9112 ] ] x1 ] 9 [ E%ﬁ%§r9r13111?<112 ﬁx11211ﬂ %%$O1 %%% 7g2c1817191811 6113i. @@ iii %% §91% % * 5101 %7.1011ﬂ1§1 31%?61 %%% E.%—61Siiﬂr. [ 162 ] x11E—1=— : E—C4 §@% %§ * 1O1%£z : 3§% 9 - 1 %$ﬂ / 511¥ﬂ é<1i Q éM %%% 111%?1 7EH4 [ 163 ] 1111 1 4d% : ¢2% %$a4@ 3 i%% 1ng / m1 0.01 — 0.1. mM 3 W %% 100 ng / m1 1 - 5 mM. . . . . [ 164 ] ﬂﬂﬂﬂPr£ﬂ 73% * 1O1§fé : ‘ : Efa911 H181O1 10H11 O1 44 ‘361% O * 31Efé. Brﬂ§ﬂPrﬁ% %§rﬂ / \1E1 ii %% %1. 0.1ng / m1 , a W %% 11 10ng / m1~% gg §E1. * O ] %§ ; : E%% ﬂﬂiﬂ$ﬁ<>ﬂ H1 ' 81O1 %%@o11 / \1 1013171351311 910 6 Eﬂ i101‘ : $111113 2i ﬂﬂﬂ ‘211 : 1. [ 165 ] 21714 x1133 #% QQQ %%o11 d191 Z1 6 $431 %%.9.§ % : 1 - 617 ] 91am. 3. 010 mm 12 - 10 g 11111 41 N 11 111 11. 1 101 g 11 111 r>v 91 Q 4 1111 —1m m >4 E E E _0. 5. 11 111 22 a 12 E 11 E g o1o o11 1110 11 1 : 1 [ o 11 111 _9. 111 a $ 99. 4. [ 166 ] ii. . . * 1O1iéféz : %§ri / ~1 * 1O ] %§Z : E% ( kg% U. i% ll 00. . a z : %%1 0.5~ 1 [ 1g 0.1 ~1 mg 0.025 ~0.05 mg / kg 5 ~50 mg / kg. . % W%% 50 ~ 100 11g 10 ~20 mg 2.5 ~ 5 mg / kg 500 ~1000 mg / kg. . . . . . . . [ 167 ] m %%o11x1.9 ﬂﬂﬂ 01 %%% 43.10117 ] ww %%£i %0s1914. X152£ %%4 A1E9o11x19 ¥ra2x11¥1 §% %Eﬂ : 21015 M 991 : 1. E E1 2 ; 119. _0. E 1110 00 EE 44 E Oh W [ o 55 § 3 8 ‘~< _O , 02L M 010 _>“ , 11181 0111 O11 111 0 0111 i ii \1 010 91% é. 19. . . . . . . . . WO 2013 / 077617 PCT / KR2012 / 009842 99 i / E1 91 EEE EEE E191. [ 168 ] E 3 * 1O1EEZ : E9& EEEAw ] . EEEE 0.025 - 0.05 mg / kg 5 - 50 mg / kg. 991% E 2.5 — 5 mg / kg 500—1000 mg / kg EEEEEEEE * 1O ] %EZ : E%Q 7§$93mgﬂ<g 9191. [ 169 ] m1191 / 11 J1E91EE W21911711E191E E 91E * 191EEﬁEE E EEEEEE 9% EE EEE E x ] * 1O ] ELEZ : . J_ 9 E 0. 025 mg / kg / day + EEEAm 5 H@@mm4Eﬂ“K47% ] 3E * E%Z%@&ww + %$ﬂ% ] ﬂ ) mg / kg / dayE o1 2 } : o1.%_% ﬂo ] O1o1 ] ; ‘|_. [ 170 ] 917191E 71 8 EEE E 91O1 EE911 / 11 z19191 —r - 91E EE9 EEE EEE €#%$ﬂW1 ] %%%111W%4Nmﬂg% , 4ﬂﬂ§ﬁ E%%1Wﬂ 2.9mg / kg9 1919112 EE 91E91 91E. 9 - 1 111111111919 L1131H171919111E EEELMEL ] 111 * 1O1EEZ : EE4 91E 915 1117<130 : 1917191 EEE Zi£E EEE ‘21 , 1191. [ 171 ] E91 EEEEEé4 7351 - / \19 1E EEE Eo11 919191 111 EE °6191EEEEE EEEEE 91 EEEEEﬁ4u 91961 91EE 25 M191300 : 191 19 , 1 EEE EE E01 11111111111 71 EE EEEEEE. [ 172 ] E9 91F O1EE4 91E191EE E E1019171 111 911E911E EEE E911 EE 912119194E E911 LL1E EEEx11991E EEEEE 911909131 . [ 173 ] EEEE 24 MM E26911 EEEE 111. [ nq E24mﬂE2@14EEm9E%1M11EE¢EEJ$1EEEﬁme® 9.1 / \1911E1—E<>1111E91 EEE E01131 EEE 912119 E EE EEEE EEE 919191 E E1914 EEE / 1913114 EEEEE EE 91E91 EEE 911961 EE 91.91 E9191 11110191 91111111119194 9 1111 : 99191214 91 E1119 EEEE EEE E EEE O11E91 E 9191 0 91 EE E EEE 111151 % * 19 EEE 91E17<191E EEEEET 1 ' i 99111i - ‘1a9s154 EE EEE EEEX11X1E 911171E91 71 9 E EEEE 111. [ 175 ] . [ 176 ] 911911911 1. 919191 911911. n77 ] 1.1 } 1914 : 9E. [ 178 ] EEEEE E EEEE E1 1L1X112°1X11X1. [ 179 ] EE 1g. [ 180 ] 961719 9¢1EEEE191E71EEO11E919191 111E11E91O1B1. [ 181 ] . 1.2 91 X114 211E. . 20. WO 2013 / 077617 PCT / KR2012 / 009842 [ 182 ] EE 9179121 E EEEEEE91L17<11 2 9121191 100mg [ 183 ] % * } F‘ * ) F‘3j3ﬁ : 100mg [ 184 ] 111111xnng U8ﬂ &ﬂ1d91&9L19HE2mg [ mm %ﬂEEEEEEﬁHEE%EEEE9MﬁH#WW19EEEEE9E EEEEE. mm ] L&ﬂﬁﬂQﬂ& [ 188 ] EE C - 17<11?<11 E EEEEEE191L1z11 2 94121191 100mg [ 189 ] 31“ / ‘1 [ 1‘1“3iy1f 100mg [ 190 ] 11E111Knng [ 191 ] ﬁE11O1%ﬂ‘ 131 : ”11? 2mg [ wm %ﬂEEEEEﬁE¥EE%EEEEEEEEEEEEﬂEﬂE9%M1 EEEEEEEEEEEEE. [ 193 ] 1.4 E41z11E z113 : [ 194 ] EE 91 X11211 E E LﬁELEE191L1X11 2 E1 211 X1 100 m8 [ 195 ] E } L1%§1801mg [ wm N@HHL1ﬂLO26m ; [ 197 ] %?111?‘2974 - m8 [ w& %ﬂEEEEEEE9%E$9EEEEEEEﬁEM9E9EEEE. n% ] [ mm ﬂﬂsz%Eﬂﬂ [ 2011 2.1%E91E1E ( 3 : E1EE ) E x19 : [ mm EEﬁﬂWH%Eﬂﬁ%Eﬂﬂ%ﬂ2Eﬂﬂ05% [ mm EE4&EEE1o% [ mM EEEEEE20% [ mﬁ EEEEEEE2o% [ mm EEEMmEEﬂE01% [ mﬂ Edﬂ42EEﬂEwﬂE82% p% ] ~EﬂE9WEEm04% [ mm EEEMm% [ mm EEhW%E®E01% [ MH EE9AM ; EEEE [ 212 ] E 211E t0 100 % DB ] 22E%EEE@EE%hEﬂE [ 214 ] EE ‘111211411 191 EEEEEEE L121 2 91%11211 0.5 % [ mﬁ ﬂﬂ4&%EﬁJD% [ mm EE4o%. pn ] . EﬂEﬂdEan5%. 21. WO 2013 / 077617 [ 218 ] 2513 ] %x1 ] ! : ﬁ%a ] oU : 1.5 % [ mm %%ﬂ%%0y% [ 220 ] 7 ] E%?4 / ? } E?%Eﬂ ith ﬁﬁﬁﬁﬁﬁ 5.0 % [ 221 ] %ﬂ 21 ] % 3.0 % [ 222 ] %%8ﬂ%vﬂ% 3.0 % [ 223 ] E§l§1§ﬂ§ﬂ§ 3.0 % [ 224 ] 7 [ E% / \ ] H1é%ﬂ U1 0.1 % [ 225 ] Eﬂ 011%%O } E£1 0.2 % [ 226 ] H8ler1L 4% ] A ﬁﬁ 75 ] 88 [ 227 ] 8 2 ] ] 5 ; : t0 100 % [ 228 ] 2.3 33 ooEELﬁa 9% 8153 [ 229 ] ﬁﬁ 9% X1 ] X1 ] %% E%£%$E } U ] L + 7<ﬂ 2 94 21 ] z1 ] 1.0 % [ 230 ] H11E } - 1 , 3—%$Z } 5 0 % [ 231 ] ‘$21113 10.0 % [ 232 ] iii €413 ] 01E 60 1.5 % [ 233 ] DJ 01 X1 60 8 ﬂﬂ U } ?< } w9r 2.0 % [ 234 ] %H1 EH11 iii %E1 ] 0 ] E 0.5 % [ 235 ] %%‘ﬁ + £ ' + l : ﬂ 10.0 % [ 236 ] £2¥CQ13E 5.0 % [ 237 ] 7 } E%?4 / 7 } E?4Eﬂ %?J HWrOE 5.0 % [ 238 ] QQ ﬂ % 5.0 % [ 239 ] 31%8ﬂaﬂg - 3.0 % [ 240 ] Eirgﬂ§ﬂ§i 3.0 % [ 241 ] Ewﬂ O11 %%O } E1 0.2 % [ 242 ] 111122 ] , 4% i , 88 : 3 8 F8 } . [ 243 ] . 7E4 , ﬂ ] ? t0 100 %. PCT / KR2012 / 009842. WO 2013 / 077617. [ %?%m. ' 0 ] 0rbl1m oTN 2. ﬁ é. oEF5E4—O { ‘ [ - { EL% * —‘W_I% ] JJ : uEﬁ0. 000. ££ : AMwéﬁHwéLE¢H$éJWm ; éﬂHnA2£m&Eé ii 2 a. 888888E8. 22. %?%%. 1%”1 ] 2101 * ] , 8‘“71. 888. W - ] m %. Q m. 0 —l * 1 21 ] x1 ] % A } O ] —§ - §3 : E. ﬂ$ﬁ , ‘3 } * } U11E } % , ﬂ U11EL%F4 $$$ €1 * §% EOﬂ H 1 : ] . %. PCT / KR2012 / 009842. §§§ ﬁﬁ %. §%% : ﬂ8§&8%. 1 Eﬂﬁ%$9ﬂ3wﬂﬂ 2Q 9%Z ] 17< ] 1 * E. 2&aH : a8§&88. Hﬂ£ L 8%EﬂHﬂ@%1%d%8ﬁ%%%2Eﬁ%0Eﬁ1 %%ﬁ%E%ﬂﬁ%%@ﬁ&8%. 1%w8lkh8ﬂE%£%$ﬂm%ﬂ2ﬁﬂﬁ% $i%ﬂﬂ&%%%2§8H : ®Eﬂﬂ%%ﬂ%8£2 .%8%@§&8%. 6%ﬂ8PV%$ﬂ%$i%%%é%%%FW%&®ﬂﬁ% %2&ﬁH : ®Eﬂﬂ$%8 “ﬂ &8%. WrXﬂ 2ﬂ 93 * ?‘11X1E - %§ / ‘é Edlfé. WO 2013 / 077617. [ %?%Lﬁ. [ %¥%M ] . [ %?%U ] . [ %¥%m ] . 23. PCT / KR2012 / 009842. ﬂMEHﬂ%ﬁHnﬁ§ﬁﬁ8VL4d%E22 . L 4d%EﬁE%ﬂEﬂﬁ%$ﬂm%ﬂ2§ﬂﬂ% 8 mmmﬂ%%M§%%ﬂE&%%%2 : a%ﬂ%&§ : : ﬂm%ﬂ8P%L§§ﬁﬂmﬂﬂaiﬂ%ﬁﬂ , ﬂﬂiﬂ$ﬁ9r Eﬂﬁ%§rEJrUWrXﬂ 2 914X11X11E1ﬂ1 18 14V1 1W mmﬂ%%Wi%%HEﬁ%%%2§a%a%§&@%. ﬂm%ﬂﬂﬂHu$ﬂ%§ﬁﬂﬂ%E% : %$ﬂﬂ%ﬂ2. ﬁﬂﬂ%ﬂ%E&8%%a 5%%% : E%ﬂ%ﬁ%%% L ﬁm%ﬂ8PVL%ﬂ‘%ﬁ3&8%£ %%i%J%4ﬂﬂ%¢8%ﬁ?hd. O. W0 2013 / 077617 PCT / KR2012 / 009842 1 / 11. [ Fig. 1 ] 12?. . . CIi8ical s - kia scor8. . . . . 8 8 ' 12 ' 18 18” 18 28 ' 22. WW mm immLGizatEcn. . d N 1. mm m8‘ ; . 8888. . 8888 £395. sm ﬁﬁﬁﬁ ﬁﬁﬁ. . . . . . . slo ' asoore C33 M 888 m m a. C|ini. . WW .1. M ' - - - .8. 88. 88 aaa ( R78 11|91£ ) lSAlKR. W0 2013 / 077617 PCT / KR2012 / 009842 [ Fi9. 4 ] 2 / 11. 10 ; . wdays 814days 821days 828days. C£in%cal 8km 8coré. . 2008 ' 150. 1e08i. mli. - ~5 ( pgfrn| ) . 508 - . . . [ Fig. 6 ] 10o08f. 800~§. 60085. m lL , - 1 3 ( pg / mI ) . 4 ( 30 - . 200. . . 88 aaa ( R78 11|91£ ) lSAlKR. WO 2013 / 077617. [ Fig. TA8C ( pg / rn0. Eotaxln ( pglm ll. . 7 ] 1 20. . 1%? 80 50 , . 408. . . 3 / 11. PCT / KR2012 / 009842. . . . . . . 1L6. . . né4HmM. ' ?ﬂ8i8 "wW. , IARchmmme. . . . 122.1 : t2$. 76§t12$. 366 : 5 ; 2633 : . . . ‘"345881 ' mm " 8316. ; 1173 mmm ' . 888881 mﬁés W W. 353?.81503 j mm " 1385.9ﬂﬂ. . . . §76§1E1£5 29i2$1237. " ‘—esw _. ' mthA. . Hm8114 . : amnes f 111M139 18.98851 f. 111138181 ' . . . "19&8aA. . . 1 1m - . 8888888 41.18898. 8828=28 * ~ smms". . : 2W8818w. - 2§4871ﬁ?ﬁ * . 3&2t83‘ _ ' . . él315=1w1. 2 : 3.92t16J‘. 83 ; I85S * Q. . 1385 : : 286‘ - : 14.7818 * %. . . . . . m 54.6£2£ * * W3§wﬁ§z. 1933 : 3 ' 1W ' . . E 2. . m mm 8. mm 88 mmmwm. 88 p86” , . pg / ml. . §§%. . . mam - w. . 9088s41113881.1f_1 f. . mm ghimm ' im Urét of m 88 mm mgAc9 . .1 . .?“”j ' 5 . . II ( 7713! 11|91$ ) |SAIKR. W0 2013 / 077617 [ Fig_ 10 ] 30 25 2O? . mm CD13 calls / flew. . CD1 + CD25 + T cells ( % ) . . $010® mﬁ ) . 0%1. 11113 <3%1. * P<0.05. 11111. . . Coatrol. . 1G|iiCUsamin9 ( 50ng / kg } . . 1111. I - I I - I. OO. _ ; FK—5U - 6 { ' 1 .01119 / k9 } . ' - . G.|ucosamine + - FK"506. Regu1atmy T cel!3. @@ ( 33135 0%1V\g\5 ( 3®%@%®". @191. EE Hg 11|91£ ) lSAlKR. VQ‘ Q ®\\1\ QQ 11K®. PCT / KR2012 / 009842. . . W0 2013 / 077617 PCT / KR2012 / 009842 [ F|g. M 5 / 11. . m 13 E. _1. O m . Q <~Q : W f . . . ....1. m. A. Mast cells / 51!3lc2$ Eos1nophi11s / 51EeIds. m. . . . [ Fig 13 ] . ontml. wwww ﬁm / kﬁ } . luwaamineﬁtmmg / kg ) . j G|uc£38am ine + FK - 506. [ Fig. 14 ] - 300 . 111 Mast caHs x Eos1nophils. 2oo. mm. . Number of lnfiltrated Cells. . . . E E %I| ( 771$! 11|91£ ) |SAIKR. W0 2013 / 077617 PCT / KR2012 / 009842 [ Fig - 15 ] ' 6 / 11. m. 50~. Serum |gE ( ; z§ / mi ) . . [ Fig. 16 ] . . . . . . . . . . . E E %I| ( 771$! 11|91£ ) |SAIKR. WO 2013 / 077617 PCT / KR2012 / 009842. . . . . . . . . . . . . . . . . . . . . . . . . . . . [ Fig. 17 ] 7 / 11 80 11 ' * * ﬂ—cm + mw 60 . Cs1 , 5 + =£—ar~ﬁf~1a1 Cs1.5 + §~ : a~£ ) ~h ' il 1111111‘ . C11t5 ' ' I 40 ' ii 20 . " 0 . - . . . . . 11§10%—J 11%24%1 12§9% 12§18% 12§3D?a1 1%9=% 1§24% 45 CE Cs2 + §§iﬁﬁEE I - - - - 40 . - - ‘_ ( 3 ] .ﬁﬁm1111t ' l _ M - _ - . - cs1.5 + ~ge$ﬁ51ﬂ : : éAWWmh”mM. Mm.=34 ' ° 25 29 15 10 ' 11 ._ . . . . 11%1?%_1 12§39él 12%15% 12§3D°Ef1 1%14% 1§3B% [ Fig. 18 ] SCORAD vs T|ME ( Tota| : N=10 ) mm 53.3 9 CC 8 ‘126.7 0. o0‘.0 . SCORAD vs nME SCORAD vs nME aa 0 ( SEO1 : N=5 ) ( SEO1 : N=5 ) . SCORAD. 26.7. . . . 0.0 100.0 20U. U 300D 0.0 1D0.0 200.0 300.0 TlME ( day ) T|ME ( clay ) . E E %I| ( 771$! 11|91£ ) |SAIKR. W0 2013 / 077617 PCT / KR2012 / 009842 [ Fig. 19 ] 8f11. SCORAD VS Tl ME ( TOtal_LOESS_DFiUGIN=10 ) . 80.0 . . . . 53.3 D E 8 m 26.7 0.0 I ' U I U l U I I d I I I I I I 0.0 100.0 200.0 300.0 TlME ( day ) SCOHAD VS T!ME SCOHAD VS TlME ( DFIUGLLOESS : N=5 ) ( DHUGO_l_OESS : N=5 ) . 80.0 80.0. SCORAD. . . . T|ME ( day ) . . . . . . . . 4. . E E %X| ( 7?”3! 11|91£ ) |SAIKR. WO 2013 / 077617 ‘ . PCT / KR2012 / 009842 9 / 11 ' . . $111M 7 " " 7 §70271 ' ‘ . ControLCsxéﬂ. . . 7L ' f ' 4 ‘. . GAPDH. \. . , SCORAD ' 7 ' é . ' 725 az 515 445 47‘ ' 34 V 375 34. . m 8. !FN - - 7 : L - 5" ' GAPOH. . 3% §%I| Ha 11|91£ ) lSAlKR. WO 2013 / 077617 PCTIKR2012 / 009842 10 / 11. [ Fig. 23 ] . iL - 4 expressi0n in sing|e vs c0mbined administration. . . " - ' 2.&. } i_ - . S - ' =. 0A - %. iii‘ ; - “ C . 00000 icomtm ' ned. §§¥ERQ%§. o.3 . 1 mn - ce ; . : - . - _ - _ : - u A. . o.2 ; . 0.1. ; 1 : . 0075 ' i _. . . - - . >. .77 u I . " . * ‘. - * r - $ , .""‘ - \ . w ~ . !1 . ' a 0 |. | - i H : , . ' I ll ; I m d " ¥a J _O ' 1 . 7 w . ﬂ . F : “u : . , - .‘.\““. ‘ . ' 7 F , J , o 7 77 II F l. : . . ; V ' I. l a. . . ' - ' L ' ¢_ ' : u_p 15 : ! d. |‘ * _ , j. . . . . , ..“"T" O. . . . . . . . . . . “0.3 i : . Mean change of |L - 4 expression. aaa $3.53. : i - Z - f - iirW iiiiiii ' ?‘. é . i. — - = - —. : - - - %— - ¢ - . - =e= - w— - : —= - % - ‘? ' . . . 0.5 ' 1 2 3 4 5 6 7 a 9 1o 0000 Patients , . e : . g57. : ¢ - . - ; : 3g. g. ¥m0.02. . . [ Fig. 24 ] . 001mm ) on ( 4sonm ) . . . . . . . . . . om4som ) . 0 mm m m m. WWW , . E 3% %X| ( 7 : 173 Xi|91£ ) |SAlKR. WO 2013 / 077617. [ Fig. 25 ] . . . PCT / KR2012 / 009842. 11 / 11. . . m. °mmon<srmu. ' 0D ( 4.50am ) . [ Fig. 26 ] . . Q.6L 1. . bD ( 450nm ) . \ - - a. - 2 ; . * mm. . o.6. o.2 7. iii. . . . 400 - ; u i 5 m‘ - . 777 . , _ 12 1 - . 0.4. . . Conmmmm ' . ‘IL - 5. 00. p ; w 1 . _. . 92‘. - 3oD - g§5onm ) - " g. . _ 9 G N 2. . . T. . m. . 0 ' 7 - . . 0 m 1. 7 C9§1cenira¢iwtnslmb. ' 79DI450 ' nm ) . ' 500 ' . m. 9 cc. . ._ f ; s‘> , . 2 99. L J. . l. . o. . WW1 1W IW { m3. Conmtmtimgii ) ‘. 0. 3% §%I| Ha Xi|91£ ) lSAlKR. . INTERNATIONAL SEARCH R_E } 70RT. In tematiena ] appiieatien Ne. PCT / KR2012 / 009842. . . A. CLA S SiFICA ' IION OF SUB JE CT NIA ' I"_E"ER A6IK 38 / 13 ( 2006.01 ) i , A61K 3I / 44 ( 2006. 01 ) i , A61K 39 / 395 ( 2006.01 ) i , A6IP 1 7 / 00 ( 2006.01 ) i. Accerding m Internatienai Patent Classiﬁcatimi ( 1I ( .‘. ) 0r ie bnth natimial c1assiti£3aiieii and. IPC. . B. FIELDS SEARCHED. . Minimum di3cnmentati0n searehed { classiﬁcatimi system i701iewed by c1assificatinn symbels ) . A61K 38 / 13 ; A61K 39 / 395 ; A61K 47 / 36 ; A61K 38 / 00 ; A61K 45 / 00 ; A61P 17 / 00 ; A61P 31 / 00 ; A61K 38 / 16 ; A61K 31 / 7028. . Deeuinentatien searehed ether than ininiinum d0e ' urnentatien t0 the eXtent that sueh d0c ' uinents are ine1udedin the tields seai ' ehed K0rean Utility m0dels and applicaticns f0r Utility m0dels : IPC as ab0ve Japanese Utility models and applicati0ns for Utility models : IPC as ab0Ve. . Eiectrenie data base ceiisulted dining the internatiena1 search { name 0f data base and , where praetieable , search terms used ) eKOMPASS ( KIPO interna1 ) & KeyW0rds : at0pic dermatitis , immun0suppressant , immun0suppressant , cyc10sp0rine , Tacr01imus , inhibit0rs 0f transglutaminase 2 , Gluc0samine , Gluc0samine. . . . . C DOCUMENTS CONSEI ) EREI ) ' i" ( } BB RELEVANT Categmy? Citatien 0f dneutnent , With indicatitm , where apprepriate , ef the reieV - ani passages ReieVant t0 elaim N0. X KR 10 - 2010 - 0099849 A ( DONGGUK UNIVERSITY INDUSTRY - ACADEMIC l - 7 , l0 - 12 , 16 A COOPERATION FOUNDATION ) 15 September 2010 8 , 9 , 13 - 15 See claims 1 - 8 , paragraphs [ 0010 ] , [ 0028 ] , [ 0033 ] . A KR 10 - 0969634 B1 ( KIM , SOO YOUL et a1. ) 14 July 2010 1 - 16 See claims l , 5 , and abstract. A KR 10 - 1993 - 0702014 A ( LTT INSTITUTE CO. , LTD. ) 08 September 1993 1 - 16 See claim 1 , and abstract. A JP 2010 - 518130A ( POLICHEM S. A. ) 27 May 2010 1 - 16 See claims l , 8 , 14 , and abstract. A KR 10 - 2010 - 0017998 A ( KIM , HYUNG RYONG et al. ) 16 February 2010 1 - 16 See claims 1 , 2 , 4 , and abstract. . . . Further deuiineiits are 1isted i1 ] , 1i ] € centinuatien ( ) ‘fBiJX C. . . . I ee patent iatmly annes. . * Speciat categeries C ' T cited dee - uments : . " " €J0eument deﬁning the generaI state cf the art whieh is net 0011sidered iii be cf particuiar re1evanee. cited m establish the puhiieatien date cf anether citatien 0r ether special reascn ( as specified. ) decument rei ' eiring te an erai disclesme , use , exhibiti0n 0r cther means deemnent pubhshed pricr tc 01e intematicnai iiiing date hnt Iater than the prierit ' y date ciaimed. “F." earlier app1ieati0n 0r patent but puhIi shed 011 01‘ after the internati0na } “ : ti1ing date “If” dneument Which may threw dcubts en primdty cIaim ( s ] er Which is. “T” later Li - DCLiIIlBﬂi. puinshe - d after the in ternatienaI fiiing date er pricrity date and net in ccnthe - t with the appiicatien bnt eited te nnderstand. the prmeiple cr tlJeery nnderiying the iriVenti0n. “ decurnent ef particular reieVance ; the eiaiined iriVenti0n cann0t be eensidered nevei er cann0t be ecnsidered t0 inyet ' ve an inventive step when the d0e1 ' : ment is taken aiene. “Y” decurnent ef particuiar reievance ; the ctaimed inventitm earinet be eensidered te in ' veive an iny ' enti ' ve step when ﬂie deeument is Cernbintxi witb 0ne cr inere cther such ( l0C1 ] 1ﬂ ents , sueii ccrnbinatien being ctwieus 00 a perscn ' 3\1i_i1€d in the art. 66&?7. document iiieiiiber Of the saine patent famiiy. I. . Date cf the actua1 ccinp1eti0n cf the internati0nal seareh. 26 FEBRUARY 2013 ( 26.02.2013 ) . Date 0finai1ing 0f the internati0na1 search rep0rt. 28 FEBRUARY 2013 ( 28.02.2013 ) . . Name and maibng address Of the ISAfKR. 33 ‘. K0rean Intellectual Preperty Ofﬁce. \\_ GoVernment Comp1ex - Daejeon , 189 Seonsa - ro , Daejeon 302 - 701 , Repub1ic 0f K0rea. FaesiniiIe N0 82 - 42 - 472—7l40. . . . Autheriaed ctfieer. Te1epi30ne Ne. . F0rin PCTfISA / ‘ZlU ( sec0nd shcet ) ( July 2009 ) . . INTERNATIONAL SEARCH REPORT { nferinaticn en patent famiiy ' members. . . Internatienal appiiwtien Ne. PCT / KR2012 / 009842. . . . Patent d00urnent Pub1icati0n Patent fami1y Pub1icati0n. cited in search rep0rt date member date. KR 10 - 2010 - 0099849 A 15 09.201O NONE. KR 10 - O969634 B1 14 O7 2010 EP 2094277 A1 02 O9.2009 JP 2010 - 506908 A 04.03.2010 US 2012 - O156137 A1 21 O6.2012 W0 2008 - O48076 A1 24 O4.2008. KR 10 - 1993 - 0702014 A 08 09.1993 EP 0547229 A1 23.06.1993 EP 0547229 A4 10.11.1993 JP O5 - 310591 A 22.11.1993 U8 5504068 A O2.04.1996 W0 93 - 00106 A1 O7.01.1993. JP 2010 - 518130 A 27.05.2010 AR O65318 A1 27.05.2009 AU 2007 - 346756 A1 21.08.2008 AU 2007 - 346756 A2 24 O9.2009 CA 2675568 A1 21.08.2008 CL 4422008 A1 22.08.2008 CN 101641082 A 03 O2.2010 CO 6210803 A2 20 10.2010 EA 200901112 A1 26 O2 2010 EP 1958613 A1 20.08.2008 EP 2117500 A1 18.11.2009 |L 199841 00 15.04.2010 KR 10 - 2009 - 0119878 A 20.11.2009 MA 31238 B1 01.03.2010 MX 2009008515 A 20.08.2009 N0 20092998 A 14 O9.2009 US 2010 - OO62083 A1 11.03.2010 W0 2008 - O98634 A1 21.08.2008 ZA 200904945 A 29 O9.2010. KR 10 - 2010 - 0O17998 A 16 O2 2010 KR 10 - 0979102 B1 31.08.2010 KR 10 - 0989045 B1 25.10.2010. . ani IC ' , I ' 7ISAj2i0 { patent fainiiy anneX } { Ju1y 2009 ) . . . 3‘R11%%11i1 : 9 : . . . % 7 * 11 i A1E 1 A1 PCT / KR20l2 / 009842 A. ‘2% D1 %91‘ : 7%1 %R ( 5t?<11% 51%7ET ( IPC ) ) . A6IK 38 / 13 ( 2006.01 ) i , A61K 3I / 44 ( 2006.01 ) i , A61K 39 / 395 ( 2006.01 ) i , A61P1 7 / 00 ( 2006. 01 ) i. . B. _7 : A1% ErOk. . 3EA1E %i%91 ( j?2111%91%7€7% 71F11 ) A61K 38 / 13 ; A61K 39 / 395 ; A61K 47 / 36 ; A6lK 38 / 0O ' , A61K 45 / 00 ; A6lP17 / 0O , A61P 31 / 00 ' , A61K 38 / l6 ' , A6lK 3l / 7028. . . . . . . . . . . . . . . . . . . . . . . 444% 71%‘eo1c 1 49 : aase 01919 RR 91%??4888 9173 - 1 - 12 94 aiiLe711 / s1787 / L1Cdsna4e 71£—Ecs‘an11 71711%1PC %e%%8%89%R Q %e%718%ﬂ<41%R : 3 : 49 ?1£—Ec9d%011 71711%1PC it711£41O11 O1%e7s14~11111R1101ﬁ ( E11O1E1R11<h / : 1 94 ss 91 @éRO1 ( 5110017 : sa> eKOMPASSC : 017§ 141% 7QAl1A1i‘. E11 ) & 7174 ‘1 . O1 - E ﬂ j4lerE1 , EO31O—1?i11?i1 , immunosuppressant , cycl0sporine , Tacr0limus , JEQé - §“ErE11311 - 71R11 2 91181811 , %—Er.3 : 1_ * 117_1 , ( } luc0samine C. 8888 71E11n?1 * 299ee 9 : e 7e ( 71ss ] s 999 71211 99 717721 K KR 10—2010—0099s49 A ( % %74191ﬂ 219 99 1 : 1 ) 2010.09.15 1 - 7 , 10 - 12 , 16 A 2?91 - 1—s , se [ 00101 , [ 0 O281 [ 003 3 ] s , 9 , 13—15 A KR 10— 09696s4 Bl ( 74 * ‘32 91 ) 2010.07.14 1 - 16 7% } ?81 - 1 5 m o@ ] : i12 A KR 10—199s—0702014 A ( 7 ] 4=LA ] 77 ] 7 ] 01A1 ; eee 73177.7 : ) 1993_09.0s 1 - 16 41%91 - 1 , 2 RC4 71%. A JP 2010—51s130 A <seeo1oi1¢ 1 O1 ) 2010.05.27 1 - 16 %%21 1 , s , 14 , a 99477 22 A KR 10— 2010— 0017998 A ( 7.4 9se ) 2010.02.16 1 - 16 2 , 17911 , 2 4 , s ; 994 717 } . %71%9ﬂO1C ( 7114‘7 ) o11 71 211F1<>1 9.1%914. %%‘51 011 12 HaﬂE 71 } .818 * 19. * 777 RRR ' 77 77739 T 9999 RR 4419 401 ] s71—9 sess. es4Asas ] 2 ] “A” aaa ggg gi‘ ; 7—10§Eo ] ‘C gu121o177 ] E$%%xgq@E4e - d §§E4 @330 71a7 ﬂE 93E11Jr O1f1f.“€ 0161151719191108§ E 777799741772797§ RRRR 7777 777 7 77777 77 “X” eee eee 99 se aa se 614a2e 2979 999 2 ss ae 999 01 91% 22222 aeE / s 0%% 76E%nEe E0 iist %7° _ _ _ L 12942 %O7‘7§9101%77017 + 7%“3e1 ) %s191771 a 7 44 : 49.19 “Y” §§§§§§§§§§ﬂi§ §§ , O ] , jfj , ; ] * ; , 4 iiiii o 77 71A ] ss w as 70a ] 4% mm ss ss % 4W3°1 ‘31E 3333 99 L a O “P” sss 999 ssssss aaaaa o m sss se “&” ﬂﬂ 4%%t17390117‘751% ﬂ j?211&4194 4171 ] 999 it711£41aﬂ41 sss 20131d02%26% ( 26.02.2O13 ) 2013 d 02% 28%1 15A / KR94 ss 94 %Yd%% 444 : sss ni__ ' u ] § 82 - 42 - 472 - 7140 ﬂﬂﬂﬂ 82 - 42 - 481 - 3371. . . . A141 PCT / ISA / 210 ( Fr 9. ] 711 sx ] ) ( 20091e 7e ) . %ﬂ§ME1H. . . %ﬂ%%8§. . . . 91%%31 011 88 41E PCT / KR2012 / 009842. : : : ; §égﬂH %4% W£%ﬂ%% %4%. KR 10 - 2010 - 0099849 A 2010.09.15 ﬁﬁ%%. KR 10 - 0969634 B1 2010.07.14 EP 2094277 A1 2009.09.02 JP 2010 - 506908 A 2010.03.04 US 2012—0156137 A1 2012.06.21 WO 2008—048076 A1 2008.04.24. KR 10 - 1993 - O702014 A 1993.09 08 EP 0547229 A1 1993.06.23 EP 0547229 A4 1993.11.10 JP 05 - 310591 A 1993.11.22 US 5504068 A 1996.04.02 WO 93—00106 A1 1993.01.07. JP 2010 - 518130 A 2010.05.27 AR 065318 A1 2009.05.27 AU 2007—346756 A1 2008.08.21 AU 2007—346756 A2 2009.09.24 CA 2675568 A1 2008.08 21 CL 4422008 A1 2008 OB.22 CN 101641082 A 201O O2.03 00 6210803 A2 2010.10.20 EA 200901112 A1 2010.02.26 EP 1958613 A1 2008.08.20 EP 2117500 A1 2009.11.18 |L 199841 00 2010.04.15 KR 10 - 2009 - 0119878 A 2009.11.20 MA 31238 B1 2010 03.01 MX 2009008515 A 2009.08.20 NO 20092998 A 2009.09.14 US 2010 - 0062083 A1 2010.03.11 W0 2008—098634 A1 2008.08.21 ZA 200904945 A 2010.09.29. KR 10 - 2010 - O017998 A 2010.02.16 KR 10 - 0979102 B1 2010.08.31 KR 10 - 0989045 B1 2010.10.25. . 44Pmﬂmﬁm04%%ﬂ%ﬂ%ﬂme87% )